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Abstract
USING SIMULATION OPTIMIZATION TO CONSTRUCT EFFICIENT SCREENING
STATEGIES FOR CERVICAL CANCER
By Christodoulos Foufoulides, B.S. Mathematics
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of
Science in Operations Research at Virginia Commonwealth University.

Virginia Commonwealth University, 2008

Major Director: Dr. Laura A. McLay
ASSISTANT PROFESSOR, DEPARTMENT OF STATISTICAL SCIENCES AND
OPERATIONS RESEARCH

Cervical cancer is the second most common type of cancer in women worldwide.
Because cervical cancer is usually asymptomatic until the disease is in its advanced stages,
cervical screening is of central importance towards combating cervical cancer. Alternative
screening strategies are evaluated from an economic point of view through costeffectiveness analysis. In the literature however, studies perform cost-effectiveness
analysis on a limited number of de facto or predetermined screening policies. At present,
no attempt has been made to construct efficient screening strategies through optimization,
viii
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before cost-effectiveness analysis is applied. In this study simulation optimization is used
to construct efficient screening strategies for cervical cancer by properly timing the
screenings. The constructed strategies are highly cost-effective when a small number of
lifetime screenings is available, and are more cost-effective than screening strategies used
in practice or considered in the literature so far, indicating the value of optimal timing for
other screened diseases as well.

CHAPTER 1 Introduction

Cervical cancer is the second most common type of cancer in women worldwide
(NCI 2007). It is estimated that in the United States 11,150 women will be diagnosed with
and 3,650 will die of cervical cancer in 2007 (NCI 2007). Because symptoms in cervical
cancer may be absent until the disease is in its advanced stages, it has become the focus of
intense screening, primarily through Papanicolaou (Pap) smears. The purpose of screening
is to detect abnormal cells in the cervix before they develop to cancer where treatment is
simple and effective, or to at least identify the cancer early in order to reduce mortality and
suffering from it.
Because of the central role of screening towards combating cervical cancer,
developing methods that maximize its effect is essential and can be achieved primarily in
two ways. One way is by improving the effectiveness of the screening methods
themselves through new technologies and new understandings, which may result to the
improvement of existing screening methods, or the development of new ones. The second
way, which is also the goal of this study, is the development of screening strategies which
utilize screenings the best way possible, and hence prevent cervical cancer incidence and
improve quality of life in a cost-effective manner. In this study, simulation optimization is
used on a model that simulates the natural history of cervical carcinogenesis in order to
1
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construct efficient screening strategies (i.e., screening strategies that provide the best
possible benefits for a specific amount of recourses). Up to present, cervical cancer
screening studies only analyzed the cost-effectives of predetermined screening strategies;
no attempt has been made to use optimization to construct screening strategies. In order to
achieve this, it is important to become first familiar first with cervical cancer, its natural
history, the various methods of screening used, and the methods of treatment of
precancerous cells and cancer.

1.1 Cancer
Cancer refers to a group of diseases where damaged DNA in cells causes them to
divide and grow in an uncontrolled fashion. The uncontrolled growth causes a tumor to
form, but a tumor does not necessarily imply cancer. A benign tumor refers to all tumors
that are not cancers. Benign tumors contain cells that are very similar to normal cells. In
order for a tumor to be classified as cancer it needs to be a malignant tumor. Malignant
tumors are composed of cancerous cells that have the following properties: the cells are
aggressive (they divide and grow in an uncontrolled way), invasive (they spread and
destroy surrounding cells), and sometimes metastatic (they spread to other parts of the
body and cause cancer there as well).
There are at least 200 types of cancer, which is approximately as many as the types
of cells in the human body. Although cancer cells can metastasize and cause cancer in
other parts of the body, the cancer is always named after the place it originated. The place
where the cancer originated is called primary cancer. Tumors from metastasized cells are
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called secondary cancers. Different types of cancer have different degrees of
aggressiveness, invasiveness and different probabilities to metastasize. Different types of
cancer also have different symptoms and behave differently to different types of treatments
like chemotherapy and radiation.

1.2 Cervix and Cervical Cancer
Cervical cancer (or cancer of the cervix uteri) is cancer on the cervix. The cervix is
a narrow, tube-like portion of the uterus that connects it with the vagina. Cervix means
“neck” in Latin, so “cervix uteri” means “neck of the uterus.” Approximately half its
length is visible with appropriate medical equipment; the remainder lies above the vagina,
and beyond view. Figure 1 shows the cervix as part of the woman’s reproductive system.

Figure 1: Female Reproductive System and the Cervix (CHUK 2007)
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The cervix is separated into the ectocervix which is made up of skin-like cells and
the endocervix, which lies underneath which is made up of glandular cells. Since they are
different cells, they can have different types of cancer. Cancer on the extocervix is called
squamous cell cervical cancer, which is the most common type. Cancer on the endocervix
is called adenocarcinoma of the cervix. Medical treatment for both cancers is the same.
The area where cervical cells are most likely to become cancerous is called the
transformation zone, which can also be seen in Figure 1.

1.3 Risks and Causes of Cervical Cancer
A risk factor is anything that increases a person's chance of getting a disease.
There are many risk factors for cervical cancer, but the most important one is the human
papilloma virus (HPV). HPV refers to a group of viruses. There are more than 100 types,
or strains, of HPV, only some of which cause cervical cancer. Other strains cause other
diseases such as skin warts and genital warts. HPV types that can cause cervical cancer are
called oncogenic or high risk types. In recent studies, HPV DNA has been detected in up
to 99.7% of all cervical cancers, and infection with one of four high risk types of HPV
(i.e., 16, 18, 45, and 31) accounts for approximately 75% of all cervical cancer diagnosed
each year (Goldie et al. 2004). This essentially makes oncogenic HPV a necessary cause
of cervical cancer. HPV is a sexually transmitted disease (STD), therefore women who
have unprotected sex or many sexual partners have a greater chance of getting oncogenic
HPV, and hence, cervical cancer (NCI, 2007). Although oncogenic HPV is an important
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risk factor for cervical cancer, most cases do not develop to cervical cancer but are
naturally eliminated by the immune system. Therefore, other risk factors are still
important to the development of cervical cancer by acting as catalysts and hence increasing
the risk of HPV progressing to the development abnormal cells and possibly cancer. The
most important such factors are smocking, diet, having a weakened immune system (due to
HIV infection, for example), having many children, and family history.
1.4 Symptoms Associated with Cervical Cancer
Precancerous abnormal cells are usually asymptomatic. Furthermore, early stages
of cervical cancer are often asymptomatic as well. That is why cervical cancer has been
the focus of intense screening for prevention, which will be the focus of Section 1.6. The
most common symptom of cervical cancer is bleeding from the vagina at times other than
during menstruation (i.e., between menstrual cycles, during or after sexual intercourse, at
any time past menopause). Some other symptoms are discomfort or pain during sexual
intercourse, and vaginal discharge with an unpleasant smell. It is important to note
however that many other conditions have these symptoms that are also more common than
cervical cancer (NCI 2007, CHUK 2007).

1.5 Natural History of Cervical Carcinogenesis
Virtually all cases of cervical cancer begin with an HPV infection. If HPV is
oncogenic, it may progress to precancerous abnormal cells called cervical intraepithelial
neoplasia (CIN). There are three levels of CIN, each one referring to the thickness of the
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skin covering the cervix that is affected. CIN I refers to mild cell changes, where one third
of the thickness of the skin covering the cervix has abnormal cells. CIN II refers to
moderate cell changes, where two thirds of the thickness of the skin covering the cervix
has abnormal cells. CIN III (also called carcinoma in situ (CIC)) refers to severe cell
changes, where the full thickness of the skin covering the cervix has abnormal cells. CIN
III means that some of the cells look cancerous, but they are all contained within the skin
covering the cervix and do not invade surrounding tissue. Within each of these stages the
disease may progress to the next state, or it may be naturally eliminated by the immune
system (i.e., it regresses), which occurs most of the time.
Once the disease reaches cancerous levels, however, the chance of the immune
system eliminating the disease is virtually nonexistent. Cervical cancer has four stages
called FIGO stages, FIGO I-IV, which indicate how far the cancer has spread. FIGO is an
acronym for Fédération Internationale de Gynécologie et d'Obstétrique; the French name
of the International Federation of Gynecology and Obstetrics. FIGO I stage indicates that
the cancer is limited to the cervix. FIGO II indicates that the cancer invaded cells around
the cervix; it invaded the upper part of the vagina and maybe the womb. FIGO III
indicates that the cancer has spread away from the area surrounding the cervix; it extends
to the pelvic wall, or the lower third of the vagina, or it may have also grown up to
block the tubes that drain the kidneys (the ureters). FIGO IV indicates that the cancer has
spread to other body organs outside the cervix and the womb. Further subdivisions of
these stages also exist. (NCI 2007, CHUK 2007)
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1.6 Cervical Cancer Screening and Prevention
1.6.1 Screening
Screening in the medical context refers to strategies that are performed on
individuals that do not have any symptoms of disease. The goal of screening is to identify
a disease early so that it allows treatment at early stages, which ideally results in reduced
mortality and suffering from the disease. This is not always the case, however.
Sometimes it is ambiguous whether the benefits of screening outweigh the costs that arise
from performing diagnostic tests and treatments. For example, if a screening strategy
detects a disease at early stages with a small chance of progressing and treatment is
imposed, the risks involved in screening and treatment (such as surgery or chemotherapy)
may not result in an overall reduced suffering and mortality from that disease. Such a
situation is called overdiagnosis. Other adverse effects of screening include stress caused
from false positive results and waste of medical recourses that are associated with them,
resources that could have been better used elsewhere.
Screening methods must be relatively inexpensive, safe, and have high specificity
and sensitivity, especially for diseases with low incidence. Specificity of a test is the
conditional probability that the test will indicate that the disease is not present, provided
that the disease is indeed not present. Sensitivity of a test is the conditional probability that
the test will indicate that the disease is present, provided that the disease is indeed present.
In other words, they are the conditional probabilities that a test will result at a true negative
and a true positive, respectively.
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1.6.2 Screening for Cervical Cancer
The most widely used method of screening for cervical cancer is the Papanicolaou
test (Pap smear), which can detect abnormal cells, ideally, before they have a chance to
develop to cancer. Treatments at precancerous levels are simple, less intrusive, more
effective, and less costly. The Pap smear is a beneficial screening method since it is safe,
easy to perform, and relatively inexpensive. In addition, since cervical cancer has a slow
progression, it allows more time for screening to catch the disease early, at precancerous
stages. Pap smears are performed by the doctor placing a speculum inside the vagina
which has arms that spread the sides of the vagina and allows the doctor to clearly see the
cervix. Then skin cells are collected from the cervix by scrapping the surface of the cervix
with a spatula or brush. As soon as the sample is taken it is spread on a glass slide and sent
to a laboratory to check for presence of abnormal cells by putting them under a
microscope. The procedure is depicted in Figure 2. A new way of performing the test is
placing the cells into a pot of liquid, which preserves the cells, instead on a slide. This is
called liquid based cytology as opposed to conventional cytology screening.

Figure 2: Depiction of a Pap smear Test (FVIVF 2007)
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The general guidelines for Pap smears in the United States are that women should
start screening at the age of 21 or three years after they become sexually active, whichever
occurs first. Pap smears should be performed at least every three years. Women 65 to 70
years old who have had three abnormal screenings and no normal screenings in 10 years
may stop having screenings after consulting with their doctor (NCI 2007). Women who
have had a total benign hysterectomy, (i.e., hysterectomy that was not performed to
remove precancerous cells or cancer) do not need screening (NCI 2007).
Other screening methods for cervical cancer are HPV DNA testing for high risk
types of HPV and visual inspection of the cervix after applying acetic acid. Each method
is associated with different costs and different specificity and sensitivity levels. Given this,
many mathematical model studies have focused in comparing the cost-effectiveness, (i.e.,
the ratio of the expected costs over the expected benefits) of different strategies using
different screening methods (Mandelblatt et al. 2002a). Even though Pap smears are the
standard method of screening in developed countries, mathematical model studies have
shown that in developing countries or low-recourse settings visual inspection and HPV
DNA strategies are cost-effective alternatives to Pap smear screening (Goldie et al. 2005,
Mandelblatt et al. 2002b).

1.6.3 Cervical Cancer Prevention
Recently, vaccines that prevent specific high risk HPV strains have been
developed. Currently there are two such vaccines available, Gardasil and Cervarix.
Gardasil was approved by the Food and Drug Administration (FDA) in 2006 and was also

10
approved by the European Union. Cervarix’s FDA approval procedures are still underway,
and it has been approved in Australia and the Philippines in 2007. Both vaccines prevent
infection of high risk HPV types 16 and 18 which account for about 70% of all cervical
cancers (NCI, 2007). Gardasil also prevents HPV types 6 and 11 which cause about 90%
of genital wart cases (NCI, 2007). The vaccine is targeted at adolescent girls aged twelve
years old because they have shown to have a better serological response to the vaccine
compared with older women, which theoretically leads to longer immunity (Adams et al.
2007). Also the vaccine works only if it is given before an HPV infection occurs. Because
the vaccines have been recently developed, there is little to no empirical information to the
cost-effectiveness of the vaccines either by themselves or in conjunction with screening
strategies. That is why many mathematical model studies have projected the clinical
benefits and cost-effectiveness of such vaccines (Goldie et al. 2003, Goldie et al. 2004).

1.7 Treatments for Abnormal Cells
If a Pap smear result is positive, it reports the level of abnormal cells by stating the
level of CIN. This classification is not strictly accurate, however, as the true CIN level can
only be diagnosed with a biopsy which is done through a colposcopy. Nonetheless, if the
classification is CIN I, the doctor may ask the patient to come back for another Pap smear
in six months instead of sending the patient to have a colposcopy or cone biopsy
immediately. If the results are CIN II or CIN III then the doctor will probably send the
patient straight for colposcopy or cone biopsy.
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Colposcopy is simply a close up examination of the cervix through a magnifying
glass that enables the doctor to see abnormalities that may be too small to see with the
naked eye. The doctor may take samples (i.e., biopsies) during colposcopy to send to a
laboratory. During a colposcopy, unlike during a Pap smear, the entire transformation area
can be seen clearly which is where cervical cells are most likely to become cancerous. If
the patient clearly has abnormal cells seen with the colposcope, the abnormal cells may be
treated the same time as the colposcopy to save the patient from making two trips to the
hospital. Cone biopsy refers to a minor operation where a biopsy of the cervix is taken in a
cone-shaped sample. It may be used either for diagnostic purposes, or for therapeutic
purposes to remove pre-cancerous cells.
If the results of the colposcopy or the cone biopsy are positive, the patient will be
asked to return to the hospital to treat the abnormal cells. A cone biopsy may have
successfully removed the abnormal cells, however. Once the abnormal cells are removed,
the treatment is complete, but follow up Pap smears are usually performed six and twelve
months after treatment for confirmation. If all follow up Pap smears are negative, then the
patient returns to her normal screening schedule.
There are several treatments for precancerous abnormal cells, all of which try to
remove or destroy the abnormal cells. The following three treatments only treat the areas
of the cervix where the abnormal cells reside; allowing normal cells to grow back:
Laser ablation: A laser beam is pointed at the abnormal cells and burns them out. It is
done with a local anesthetic.
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Cold coagulation: Abnormal cells are destroyed by a hot probe. It is also done with local
anesthetic.
Cryotherapy: Abnormal cells are destroyer by a cold probe. It is also done with local
anesthetic. (CHUK 2007)
The following three treatments remove the entire transformation zone; the area that
contains all the cells that could become precancerous or develop to cancer (see Figure 1):
LEEP stands for loop electrosurgical excision procedure. It uses a small tool and electric
current to remove the transformation zone from the cervix. It is currently the most
commonly used approach to treading precancerous abnormal cells. It has the advantage
that instead of destroying the cells, they are removed and sent to a laboratory to confirm
that the area containing abnormal cells has been removed. It is done with a local anesthetic
and the procedure is often performed along with colposcopy.
Cone biopsy: As already mentioned it is a small operation where a cone shaped section is
taken from the cervix either to diagnose or treat abnormal cells or to diagnose cancer. It is
done under local or general anesthetic.
Hysterectomy: If abnormal cells have been found on a patient’s cervix more than once, or
if the abnormality is severe, the doctor may recommend hysterectomy. In a hysterectomy
the entire or part of the womb is removed, which, like the cervix, is also part of the female
reproductive system and can be seen in Figure 1. (CHUK 2007)
Since there is some chance that not all affected cells were removed, patients need to
continue check ups. Usually a colposcopy or a Pap smear is performed six months after
the treatment and a Pap smear twelve months after treatment. After that, subsequent Pap

13
smears are performed depending on the amount of abnormal cells and if all of them have
been successfully removed. If abnormal cells reappear they are treated normally. If they
reappear more than once however a hysterectomy may be performed. Very rarely, even
after a hysterectomy, not all abnormal cells are removed so Pap smears are performed six
and twelve months after treatment.

1.8 Cervical Cancer Treatments
There are three treatment methods used in treating cervical cancer, surgery,
radiotherapy, and chemotherapy.
Surgery: Surgery as a treatment for cervical cancer refers to hysterectomy to remove the
cervix and uterus. Sometimes radical hysterectomy is needed where parts of the vagina are
also removed.
Radiotherapy: Radiotherapy uses high energy waves like X-rays and gamma rays to cure
cancer. It can be done externally from a machine outside the body or internally by placing
radioactive material inside the womb focusing radiation near the cervix and lower part of
the womb.
Chemotherapy: Chemotherapy uses drugs that kill cancer cells by disturbing their growth.
They are entered to the bloodstream through a vain so it can affect cancerous cells
everywhere in the body.
Different treatments or combinations of them are used at different states. The
chance of success of treatment is measured by the five-year survival rate, which refers to
the proportion of people that are still alive five years after diagnosis and treatment. The
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chance of a person dying from cancer after five years is extremely small, that is why this
time interval is used (Myers et al. 2000). The five-year survival varies based on the overall
well-being of the patient, the exact spread of the cancer, and it also increases as treatment
methods are improved over time. Below is a summary of the treatments used and their
five-year survival rates for each state. The estimated five-year survival rates are
summarized from Siebert et. al. (2006), as they are some of the most recent estimates used
in mathematical model studies.
FIGO I is generally treated with surgery or radiotherapy. If it is very advanced, combined
chemotherapy and radiotherapy may be used. The five-year survival rate is 94%.
FIGO II is treated with surgery, radiotherapy, or both. If advanced, combined radiotherapy
and chemotherapy treatments are used. The five-year survival rate is 73%.
FIGO III is normally treated with combined use of radiotherapy and chemotherapy. The
five-year survival rate is 59%.
FIGO IV is treated with surgery, radiotherapy, chemotherapy or a combination of them.
The five-year survival rate is 23%.

1.9 Research Objectives and Organization of Thesis
At present, no substantial attempt has been made to use simulation models to
construct cost-effective screening strategies towards combating cervical cancer. In most
cases, simulation models were used to compare existing screening strategies, such as
screening every two, three, and five years by performing cost-effectiveness analysis on
these existing screening strategies. In few cases, some intuition and experience about the
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natural history of cervical carcinogenesis was used to consider different ages to start and
end screening, and to find the best age to screen given one lifetime screening available for
each woman. In this thesis, multi-objective simulation optimization methods are applied
on a model that simulates the natural history of cervical carcinogenesis, to construct
efficient screening strategies. Such strategies are more cost-effective than strategies that
are used in practice or considered in the literature so far.
The organization of the remaining thesis is as follows: Chapter 2 presents
mathematical background information needed to perform the recommended analysis such
as cost-effectiveness analysis, and Markov process models. Then a literature review is
performed along with an argument of the appropriateness of optimization as a means of
constructing efficient screening strategies. Chapter 3 provides a full description of the
model that was constructed to simulate the natural history of cervical carcinogenesis, and
of the formulation of the optimization models used to construct the screening strategies.
Chapter 4 focuses on the analysis of the strategies given by the optimizations. Chapter 5
discusses overall conclusions and recommendations for further study.

CHAPTER 2 Cost-Effectiveness Analysis, Mathematical Models for
Cervical Cancer Screening, and Simulation Optimization

This chapter begins with an overview of cost-effectiveness analysis as the
appropriate method used in comparing different screening strategies. Then, a discussion
on the use of mathematical models as a method of considering different screening
strategies is made, along with an overview of Markov processes, of which non-stationary
Markov processes are the most appropriate models to accurately represent the natural
history of cervical carcinogenesis. Then, a literature review is performed to indicate how
mathematical models have been used to study screening strategies for cervical cancer.
Then, an argument on the need of optimization is made, indicating how it ties in with costeffectiveness analysis. Finally, an overview of simulation optimization is provided.

2.1 Cost-Effectiveness Analysis
When dealing with clinical interventions from an economic point of view, the most
common method of comparison is cost-effectiveness analysis. Cost-effectiveness analysis
compares the expected costs and expected gains of two or more alterative courses of
action. Specifically for health issues, it compares the expected costs and health benefits of
two or more clinical interventions. It is important to distinguish the difference between
16
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cost-effectiveness analysis and cost-minimization (i.e., optimization) analysis. In cost
minimization analysis, the goal is to achieve a particular task with the smallest costs
possible. In cost-effectiveness analysis, the goal is to see how much additional health
benefits can be gained per dollar as more expensive alternatives are considered.
Cost-effectiveness is expressed by the incremental cost-effectiveness ratio (ICER),
which is defined as the ratio of the difference of the expected costs, over the difference of
the expected benefits of an efficient alternative, compared to the next best efficient
alternative. Its units of measurement are usually dollars per unit of health benefits gained.
Mathematically ICER is expressed as follows:
ICER =

E (Ci ) − E (Ci +1 )
E ( Bi ) − E ( Bi +1 )

where
i = ranking of efficient alternative
E (Ci ) = the expected costs of the ith best policy
E ( Bi ) = the expected benefits of the ith best policy
Note that ICER is computed only with efficient alternatives. An efficient (or nondominated) alternative is one that for a specific cost offers the most benefits. Such
alternatives lie on the efficiency curve in the cost-effectiveness plane. If an alternative
costs more and is equally or less effective, or costs the same and it is less effective than
some other alternative, it is said to be dominated and it lies inside the efficiency curve.
Note that the cost-effectiveness ratio of an efficient alternative is calculated relative to the
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next best efficient alternative. If this is not the case, then there is a risk of incorrectly
concluding that an alternative is cost-effective.
The definition of ICER reiterates the goal of cost-effectiveness analysis, which
studies the additional costs per health unit gained as more expensive alternatives are
considered. In cost-effectiveness analysis, the law of diminishing returns is also seen,
since as more expensive alternatives are considered their ICER gets larger. In other words,
as the alternatives get more and more expensive, the amount of additional benefits per each
additional dollar spent become less and less. Once the efficiency curve is established, the
decision maker can use it to decide at which alternative, the additional costs called for (for
the next more expensive alternative) do not provide sufficient additional health benefits
and choose that alternative for the specific problem in question.

2.2 Randomized Clinical Trials, Cohort Studies, and Mathematical Models
Standard methods of measuring the effectiveness and cost-effectiveness of clinical
interventions are randomized clinical trials and cohort studies. A clinical trial is a test that
compares one treatment versus another (or no treatment) by using an experimental and a
control group of subjects respectively. A cohort study is a type of a longitudinal study
where a subgroup of a targeted group of people sharing a common characteristic is
followed within a time period. A birth cohort, for example, is a group of people who were
born in the same year. In both cases it is essential that the subjects are randomly selected
so that they represent the general population of interest.
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When comparing the effectiveness and cost-effectiveness of clinical interventions
such as alternative screening strategies, randomized clinical trials and cohort studies are
not always practical, economically feasible, or ethical (Cantor et al. 2003). In addition,
such studies can be hindered by noncompliance and dropout by the subjects. Furthermore,
making intelligent decisions regarding clinical interventions require that all the parameters
that come into play to be carefully considered. This means taking into account parameters
that determine the natural history of a disease, the clinical benefits, and costs of alternative
interventions, information on the accessibility, compliance to treatment, and so forth. A
single cohort study or clinical trial cannot incorporate all of these components nor evaluate
all possible strategies that could be considered (Goldie 2003).
Mathematical models join the best available information from different studies
and synthesize them in a single model, so that all the information needed are considered
(Goldie 2003). Also, with mathematical models, otherwise infeasible hypothetical
comparisons or questions can easily be considered. In addition, mathematical models can
not only simulate real life, but can do so at a much faster rate; a cohort of 1,000,000
subjects for example can be simulated through the course of their entire lifespan in a matter
of minutes. Hence, mathematical models can extend and extrapolate results beyond the
time-horizon of a clinical study. Mathematical models can also deal with uncertainty
involved in certain parameters, since those parameters can be varied within a plausible
range of values and see the effect that has on the effectiveness of the clinical intervention.
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2.3 Stochastic Models and Markov Processes
In order for mathematical models to aid in making decisions regarding clinical
interventions, they must be able to cope with uncertainty. This is because the parameters
that they must incorporate are probabilistic in nature. For example, some primary
parameters in a disease prevention model are the risks of getting the disease and the risks
of the disease progressing to more advanced stages. Other core parameters in such models
that are probabilistic are the specificity and sensitivity of different screening strategies, and
the probabilities of effective treatment of a disease at its various stages. Therefore, in
order for a mathematical model to properly represent such a situation, it needs to be
stochastic in nature. Stochastic mathematical models are ones that use random variables
for potential events to occur.
A simple and commonly used stochastic model is a decision tree (or tree diagram).
A decision tree uses a graph to depict a set of alternative decisions along with their
possible outcomes, their respective probabilities of occurring, and their expected costs or
benefits. A decision tree however, allows decisions to be made about one future event,
over a short time horizon. When dealing with diseases however, there are many future
events occurring over a long period of time. Therefore, applying a decision tree to such a
situation would result to oversimplifying the problem. Decision trees were used in medical
decision making until 1983, when Beck and Pauker indicated how the use of Markov
models (which will be described later in this section), is a far more accurate representation
of clinical settings (Sonnenberg et al. 1993).
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A probabilistic model for processes that evolve over time through multiple future
events is called a stochastic process. More formally, a stochastic process is defined as an
indexed collection or random variables { X t } which represent the state of the system at
time t. The values of the random variables X t represent the state of the system at that time.
If t can only attain discrete values and the number of possible states the process can be in is
finite, then the process is called a discrete time stochastic process with a finite state space.
For a cervical cancer stochastic process, t often obtains discrete values of one year
intervals and the states of the process are the states a woman can be in with respect to
cervical carcinogenesis as described in Section 1.5, at the end of each year during her
lifetime. Then, the sequence of states that a woman is year after year provides a
mathematical representation of how her health status evolves over time.
In order to perform analysis with stochastic processes however, some additional
assumptions need to be made. One such assumption is called the Markov property. A
stochastic process { X t } is said to have the Markov property if the conditional probabilities
of a process to transition to a state j at time t+1 given that it is on state i at time t, only
depend on the state i at time t. In other words, the transition probabilities do not depend on
the past history of the process, but only on its current state. More formally, the Markov
property is expressed as follows:
P{ X t +1 = j | X t = i, X t −1 = it −1 ,..., X 0 = i0 } = P{ X t +1 = j | X t = i} .
A stochastic process that possesses the Markov property is called a Markov process and
the transition probabilities are denoted by pij = P{ X t +1 = j | X t = i} . If these probabilities
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do not change over time, then the Markov process is said to be stationary. When this is the
case the transition probabilities can be displayed in a square matrix PS × S called the one
step transition matrix, where S is the number of states the process can be in. In some cases
however, the transition probabilities vary over time and the process is called a time-varying
or a non-stationary Markov process. In such a case the transition probabilities are denoted
by pijt = P{ X t +1 = j | X t = i} and there exists a transition matrix for each time t which we
denote by P t S ×S . Therefore, the transition probabilities of a non-stationary Markov process
can be thought of as a three dimensional matrix (or array), where t takes values as large as
the time horizon considered for a specific model. In both cases, because the process must
make a transition into some state (which includes the system staying in the same state) the
S

transition probabilities must satisfy the property

∑p

ij

= 1 for all i = 1,…, S. Unlike

j =0

stationary Markov processes, where closed-form solutions exist to answer various
questions, non-stationary Markov processes do not generally have closed form solutions,
so answers are often obtained by running simulation models of them over large samples.
Non-stationary Markov processes are the most appropriate tool for modeling
diseases because the probabilities of acquiring the disease, and progressing to a more
advanced stage, or regressing to a previous stage of the disease vary according on the age
of the of the individuals. This is also the case with cervical carcinogenesis. Since HPV is
a sexually transmitted disease, the probability of a woman getting infected depends on the
patterns of sexual behavior in the population of interest which vary by age. Also the
probabilities of progression and regression of the disease to and from more advance stages
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respectively, depend on the strength of the immune system of a woman, which in turn also
depends on age.

2.4 Literature Review
2.4.1 Operations Research and Health Care
Mathematical models are powerful tools that solve problems without meddling
with the real-world system, which is often a requirement for healthcare problems as
indicated in Section 2.2. Operations Research (OR), the discipline which uses
mathematical modeling along with other mathematical methods to find the best solutions
for complex systems, has been used in healthcare for over 40 years (Brailsford, 2007).
Simulation is the most commonly used OR approach in health care because it can handle
the stochastic nature of healthcare systems and the high degree of complexity that
characterizes them, whether modeling diseases or health care facilities such as hospitals or
emergency rooms (Brailsford, 2007). Among simulation methods, Discrete-event
Simulation (DES) is the most commonly used approach in health care in OR studies. This
is because DES is the most flexible simulation method in which virtually anything can be
simulated and allows modeling at the individual (patient) level and can assign attributes to
the individuals such as age, gender, blood type, etc. to determine their flow through the
model (Brennan et al. 2006). Furthermore, DES software packages allow the user to add
animation to the model, which can serve as a means of communication with non-numerate
healthcare professionals. Other simulation methods that are used in healthcare models are
Decision Trees, Monte Carlo Simulation, and System Dynamics (Brennan et al. 2006).
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From an application point of view, the majority of healthcare models fall into two
major categories. The first category is operational models that deal with healthcare units
such as hospitals or emergency rooms. Such models are concerned with capacity planning,
resource allocation, and process redesign of the healthcare unit in question (Brailsford,
2007). Operational models are classical OR applications which use DES methods and are
the most prevalent type of healthcare OR studies found in the literature (Brailsford, 2007).
One example of such a model is the Griffiths et al. (2005) study where an intensive care
unit was modeled with DES. The intensive care unit in question had a flexible number of
beds by bringing additional beds from other parts of the hospital based on demand. One
requirement of the intensive care unit however, was to maintain at least a one-to-one ratio
of nurses to patients, so supplementary nurses had to be recruited at high demand periods.
Since supplementary nurses are an expensive recourse, the goal of the model was to
determine the required number of supplementary nurses per shift that met the unit’s
requirements while minimizing the overall nursing staff costs.
The second category is called disease modeling and it models biological processes
(usually some disease progression) of the human body. Such models are often used to
study clinical effectiveness and cost-effectiveness of clinical interventions such as
screening and vaccination as means for disease prevention. One such example is the
model in the Tafazzoli et al. (2005) study where a screening structure was added to an
existing DES model of the natural history of colorectal cancer to perform a costeffectiveness analysis on the latest colorectal cancer screening strategies recommended by
the American Gastroenterological Association. Many such cost-effectiveness analyses
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exist, but virtually all of them compare a limited number of predetermined strategies,
which is an insufficient approach to determine the best timing of the interventions in order
to maximize their health benefits. At best, some studies consider the timing of the
interventions implicitly, by studying if a particular clinical intervention should be
performed in some age group. One such example concerns screening mammography for
breast cancer. Whereas mammography is recommended and considered cost-effective for
women aged 50 to 70 years of age, the cost-effectiveness of adjacent age groups is a matter
of debate. The Kerlikowske et al. (1999) study considered the cost-effectiveness of
continuing screening mammography for the age group of 70 to 79. Although this study
does consider the issue of when the intervention should be performed it does so implicitly
by considering an age group and by only considering a small number of predetermined
screening strategies on that age group, which is still insufficient to determine the best
timing of the interventions to maximize the health benefits of the screenings.
A notable exception with respect to properly timing the clinical interventions is the
Faissol et al. (2007) study which explicitly considers the proper timing of testing and
treatments for Hepatitis C through optimization. The study optimizes the timing of the
screenings by using a special case of a Markov Decision Process (MDP) called Partially
Observable MDP, where the dynamics of the model are determined by a MDP but
information on whether someone has the disease can only be obtained from testing. This
thesis takes the same approach of properly timing the screenings through optimization for
the case of cervical cancer but with a different modeling approach. This thesis uses
advances made in combining simulation with optimization to perform optimization on a
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DES model of the natural history cervical cancer to determine the best timing of the
screenings. This will be discussed in detail in the remaining sections of this chapter, but
first a literature review is performed to indicate how mathematical models have been
successfully applied to study the natural history and clinical interventions for cervical
cancer.

2.4.2 Cervical Cancer Mathematical Model Studies
An accurate natural history of the cervical carcinogenesis is the backbone of any
mathematical model that tries to assess the efficacy of an existing or a hypothetical cervical
cancer screening strategy. Due to the large, systematic literature review needed to obtain
the best available information about the parameters that determine the natural history of the
disease, some studies focused solely on constructing a model that accurately portrays this
process. For example, Myers et al. (2000) constructed a nineteen-state non-stationary
Markov model of a cohort of women from ages 15 to 85 primarily for the development of
an accurate history of natural carcinogenesis. They conducted sensitivity analysis by
varying the parameters of the model to evaluate the effects of the changes on CIN I-III
prevalence and cervical cancer incidence. A key conclusion from this analysis is that
cancer incidence is most sensitive to the incidence of HPV and the probability of
progression of CIN III to cancer.
Due to the recent understanding that oncogenic HPV strains cause cervical cancer
as well as the development of HPV-16/18 vaccines, some studies focused on analyzing the
type-specific natural history of HPV and the projected effects of such a vaccine. Goldie et
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al. (2003) constructed a Markov model that further partitions the HPV types to analyze the
impact of such a vaccine. The HPV types were partitioned into non-oncogenic HPV,
oncogenic 16/18 HPV, and oncogenic non-16/18 HPV, and they conducted a systematic
literature review to obtain the appropriate age-specific progression and regression
parameters for the specific HPV types. The study concluded that a 16/18 vaccine that is
98% effective is associated with an approximately equivalent reduction in 16/1-associated
cancer and a 51% overall cancer reduction. Kohli et al. (2007) also tried to estimate the
long-term impact of a 16/18 HPV vaccine in the in the context of the United Kingdom. In
their study, they also incorporated the fact that vaccination offers partial protection against
oncogenic types HPV 31 and 45. Their model predicted that the vaccine would result to a
66% reduction in precancerous lesions and a 76% reduction in both cervical cancer
incidence and death. Neither model has evaluated however the beneficial effects of HPV
vaccination due to herd immunity.
Ever since the wide application of organized screenings programs, the incidence
and mortality of cervical cancer has reduced dramatically in developed countries. But in
less-developed countries, cervical cancer is still a leading cause of cancer death in women,
with 80% of cervical cancers worldwide occurring there (Mandelblatt et al. 2002). This is
why some studies have focused on considering alternative cost-effective screening
strategies for less-developed countries taking into consideration the limited recourses
available. Goldie et al. (2001) constructed one such a model for South Africa. Due to
reduced recourses and compliance levels in low-recourse settings, the study concluded that
HPV-DNA or visual inspection screening strategies that eliminate multiple visits can offer
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cost-effective alternatives to cytology-based (Pap smear) screening. In another similar
study that considered the cost-effectiveness of cervical cancer in five developing countries,
Goldie et al. (2005) concluded that screening women once in their lifetime with visual
inspection, the lifetime risk of cervical cancer reduced by 25-36%. The study also
concluded that the relative lifetime risk reduced an additional 40% with two screenings at
35 and 40 years of age.
Although cervical cancer incidence and mortality have greatly reduced in places
where organized screening strategies are present, the optimal use of recourses to achieve
the best possible results is always desirable. Several papers focused on comparing
alternative screening strategies in settings where organized screening exists by considering
alternative screening methods, intervals, and starting and ending ages. Siebert et al. (2006)
constructed such a model for Germany in the German health care context. They developed
a non-stationary Markov model that depicts the natural history of cervical carcinogenesis
in Germany. They considered the cancer incidence, cancer death, and life years saved
(LYS) if the screening interval is varied from 1 year to 2, 3, or 5 years when starting
screening at age 20 and stopping at 85. They concluded that the most cost effective
screening strategy was every two years since compared with screening every year, the
reduction in cancer incidence only improved from 2,851 to 2,994 per 100,000 and the
reduction in cancer death only dropped from 1,000 to 981 per 100,000.
Mandelblatt et al. (2002) also considered screening strategies in places with
organized screening strategies. They developed a C++ program of a seventeen-state
Markov model to estimate the expected costs and expected quality-adjusted life years
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(QALY) gained associated with 18 different screening strategies. The strategies were
compared by considering three possible ages to end screening (65, 75, and until death),
three possible screening strategies (Pap smear, HPV DNA testing, Pap smear and HPV
DNA testing), and two possible screening intervals (every two and every three years).
They concluded that screening every two years until 75 with combined HPV and Pap
smear testing compared to stopping screening until death captured 97.8% of the health
benefits. Therefore, considering different age limits associated with screening is a costeffective option to maintain the benefits while reducing the costs of screening strategies.

2.5 The Need for Optimization and Thesis Objective
In all of the studies where screening strategies were considered, however, only a
limited number of either de facto or predetermined strategies were considered. Even in the
case of the Mandelblatt et al. (2002) study that considered 42 different scenarios, these 42
scenarios are a very small number of all possible scenarios that could be considered. In
fact, screening scenarios with good potential exist if the fact that cervical intraepithelial
neoplasia (CIN) and cervical cancer risks are age-dependent is considered. This implies
that varying the screening intervals, by setting smaller screening intervals at higher-risk
ages and larger screening intervals at lower-risk ages would provide more cost-effective
strategies. Considering all possible combinations of varying screening intervals, with all
possible starting and ending screening ages is immensely computationally intensive. Even
if many cases were eliminated through the understanding of the natural history of cervical
carcinogenesis, the problem would not be sufficiently reduced so that all remaining
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alternatives could be considered. In such cases, where the number of alternative scenarios
is large, the appropriate method to find the best alternative is with the use of optimization.
Optimization algorithms can find the most effective screening strategies in a
realistic time frame, since they intelligently search alternative solutions within the space of
all possible solutions. Even though optimization analysis is a different approach towards
decision-making from cost-effectiveness analysis, optimization can be used to construct an
efficiency curve first and then perform cost-effectiveness analysis as described in Section
2.1. The construction of the efficiency curve can be achieved through a method called
repeated optimization; an approach for solving multi-objective optimization models.
Multi-objective models are models where there are two or more objectives which conflict
with each other and some tradeoff between them needs to be made. Models for cervical
cancer screening strategies are multi-objective since when evaluating alternative screening
strategies there are two competing objectives; keeping costs that arise from screening,
diagnosis, and treatment at a minimum while maximizing health benefits such as reduction
in cancer incidences and cancer deaths. The two objectives conflict with each other since
more expensive screening strategies can provide higher levels of health benefits.
With repeated optimization, an efficiency curve is constructed by setting to varied
levels (values) all but one objective, which is then treated as a single objective to be
optimized. In the current situation there are only two objectives, so the efficiency curve is
constructed by setting costs at various levels and then optimizing with respect to
maximizing the health benefits. Specifying various cost levels directly on cervical cancer
screening strategies is not practical, but the number of lifetime screenings available per
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woman correlates with costs and is easy to vary. Health benefits can be defined in more
than one ways; it can be cancer incidences, cancer deaths, or the life years saved in the
screened population. Which definition for health benefits is the most appropriate is
subjective, so in this study all three definitions will be considered and the tradeoffs
between them will be analyzed. So, by specifying how many lifetime screenings are
available per woman (e.g., from 1 to 30) and repeatedly optimizing with respect to
maximizing the health benefits, the resulting solutions are screening strategies comprised
by a set of ages when screening occurs that offer the best health benefits possible for each
given number of lifetime screenings available. All optimal solutions together comprise the
constructed efficiency curve. Note that these solutions also define the optimal starting and
ending screening ages, which are determined from the smallest and largest ages provided
by the optimal solutions.
The importance of the ages at which screenings are performed has been noted in the
literature. For example, Mandelblatt et al. (2002) noticed that stopping screening at 75
instead of screening until death captured 97.8% of the health benefits. Goldie et al. (2005)
predicted that screening women once in their lifetime at age 35 can result in a reduction of
cervical cancer of 25-36%. However, the full potential of properly timing screenings,
which can be reached through optimization, was never taken advantage of since those
models only considered small numbers of predetermined screening strategies.
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2.6 Simulation Optimization
Since the natural history of cervical carcinogenesis is too complex to be modeled
analytically due to the fact that it is a non-stationary Markov Process (and due to additional
reasons that will be mentioned in Chapter 3), in this study it is modeled as a discrete event
simulation model. Hence, in order to optimize this model, simulation optimization needs
to be considered. Simply stated, simulation optimization is any optimization problem
where the objective function(s) and/or at least one of its constraints are evaluated through
computer simulation. As a result, these functions are only implicit, stochastic functions of
decision variables in the system (Azavidar 1999). In other words, these functions do not
have analytical expressions and are estimated through multiple simulation replications at
specific values of the decision variables. This makes simulation optimization more
computationally expensive compared to other types of optimization, but short of this, it is a
very powerful tool as it allows optimization of complex models that would otherwise not
be feasible. Also, simulation models have little to no compromise to their validity (which
is the degree at which the model and inferences made through the model hold for the real
system), a compromise which often has to be made when systems are modeled
analytically. Also, the complexity of the system being modeled has little to no effect to the
performance of the optimization process.
The most common formulation of simulation optimization problems is the
maximization or minimization of the expected value of the objective function of the
system. The general mathematical formulation of simulation optimization problems is:

33
Max(Min) f ( X ) = E[ z ( X )]
Subject to P{g ( X ) < 0} > 1 − α
h( X ) < 0
where z is a random vector representing several responses of the simulation model for a
given value of the decision variable vector X. f(X) is the unknown expected value that can
only be estimated by repeated observations of z(X). P is a vector of stochastic constraints
which have at most a probability value α to be violated and h is a vector of deterministic
constraints in the decision variables (Azavidar 1999).
Methods used in simulation optimization vary according to the nature of the
optimization model. The optimization problem in this study is discrete with a finite but
combinatorially large feasible space, so the most appropriate methods are metaheuristics
(Sigurdur and Jumi 2002). Metaheuristics for the most part use the same local
improvement principles as other optimization methods to intelligently search the feasible
solution space, but they do not explicitly use derivatives so no equation of the objective
function in necessary. Another key feature of metaheuristic algorithms is that in addition
to local improvement procedures, they include higher level procedures that allow them to
escape from local optima and perform a more robust and complete search of the feasible
region. Common metaheuristics used in simulation optimization are Tabu Search,
Simulated Annealing, and Scatter Search. Metaheuristics cannot guarantee the optimal
solution, but well-designed ones provide solutions that are at least nearly optimal; a
limitation which has limited relevance in practice (Sigurdur and Jumi 2002). To point out
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this distinction however, the best solution found from a metaheuristic search is sometimes
called a heuristic optimum.
For difficult optimization problems, such as the one in this study, metaheuristics
are more robust and faster than more conventional optimization algorithms. Also, due to
their ability to escape from local optimal and perform a more robust and complete search
of the feasible region, not only they have a greater chance of reaching the global optimum,
they also generate multiple alternative solutions while focused on finding the optimal
solution; something that is very useful in practice (Sigurdur and Jumi 2002). In fact, all
these advantages of metaheuristics have made them the dominant methods used in practice
and in commercial simulation optimization packages regardless of the nature of the
optimization model that needs to be solved (Sigurdur and Jumi 2002).

CHAPTER 3 The Cervical Cancer Simulation Model

This chapter provides a full description of the model that was developed in order to
perform the analysis recommended in Section 2.5. First, the general logical structure and
assumptions of the model are described, along with the parameters used. Then, the
verification and validation of the model will be discussed, which ensure that the model
works as expected. Finally, the formulation of the optimization models is discussed.
The goal of this study is to demonstrate how to construct efficiency curves of
cervical cancer screening strategies through repeated optimization, by maximizing the
health benefits subject to the number of lifetime screenings available per woman in the
screened population. In order to demonstrate this, a set of parameters that describe the
natural history of cervical carcinogenesis were required to serve as the groundwork on
which the analysis is performed. A systematic literature review was performed to identify
a model with the most clear and complete set of parameters that describe the natural
history of cervical carcinogenesis. In addition, a set of model predictions on cervical
carcinogenesis in the absence of screening was desirable, as they would allow cross-model
validation and model calibration. Examples of such predictions are: lifetime risk of
developing cancer, age of cancer incidence peak, and prevalence of CIN I-III by age. The
35
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most appropriate model available was developed by Siebert et al. (2006) which was
designed to describe the natural history of cervical carcinogenesis in Germany. The
natural history of cervical carcinogenesis is very similar among Western European
countries and the United States (Siebert et al. 2006). Therefore, the natural history of
cervical carcinogenesis in the Siebert et al. (2006) model is an appropriate template to
demonstrate the advantages of optimizing the effects of cervical cancer screenings by
determining the best combination of years to perform them.

3.1 General Logical Structure, Assumptions, and Parameters of the Model
The cervical cancer simulation model is comprised by two sub-models. The first
sub-model simulates the natural history of cervical carcinogenesis and the second
simulates screening and treatment imposed by clinical interventions. Sections 3.1.1 and
3.1.2 provide a description of the logical structure, assumptions, and parameters used for
the two sub-models.

3.1.1 Assumptions and Logical Structure of the Natural History Sub-model
The general structure of the natural history sub-model is a sixteen-state Markov
process that simulates the natural history of cervical carcinogenesis, as described in
Section 1.5, over a hypothetical cohort of 100,000 women from ages 15 to 85 years old.
Figure 3 provides a graphical representation of the Markov process where the squares
represent the health states and the arrows represent the possible transitions between the
states over a Markov cycle of one year. Each possible transition in the model has a set of
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age-specific transition probabilities, which can be thought of as a one-dimensional array
indexed over age as described in Section 2.4.

Figure 3: Graphical Representation of the Markov Process for the Natural History of
Cervical Carcinogenesis.
The sixteen states of the model, along with their possible transitions are as follows:
1. Well: There are no cell changes on the skin of the cervix.
From this state, a woman can remain in the same state, progress to CIN I, move to benign
hysterectomy, or die from some cause other than cervical cancer.
2. CIN I: Mild cell changes on the skin of the cervix.
From this state, a woman can remain in the same state, regress to well, progress to CIN II,
move to benign hysterectomy, or die from some cause other than cervical cancer.
3. CIN II: Moderate cell changes on the skin of the cervix.
From this state, a woman can remain in the same state, regress to well, progress to CIN III,
move to benign hysterectomy, or die from some cause other than cervical cancer.
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4. CIN III: Severe cell changes on the skin of the cervix.
From this state, a woman can remain in the same state, regress to well, progress to FIGO I
cervical cancer, move to benign hysterectomy, or die from some cause other than cervical
cancer.
5 – 8. Undiagnosed (Undiag.) FIGO I – IV: Cervical cancer that has not been detected
through symptoms or screening.
From these states, a woman can remain on the same stage of cancer, progress to the next
stage, develop symptoms and move to known cancer of the same level, or die from some
cause other than cervical cancer. At undetected FIGO IV stage of cervical cancer, the
woman can move to death from cervical cancer. At cancer states, regression to previous
stages of cervical carcinogenesis is not possible.
9 – 12. Diagnosed (Diag.) FIGO I – IV: Cancer that has been detected through symptoms
or screening.
At these states a woman is considered to be treated for cervical cancer according to the
stage of the cancer, as described in Section 1.8. If treatment is successful, and no
reoccurrence of cancer is seen for a period of five years the woman moves to the cancer
survivor state. Otherwise, she moves to the cancer death state. During these five years a
woman can also die from some cause other than cervical cancer.
13. Benign Hysterectomy: Hysterectomy performed for reasons other than cervical cancer.
If hysterectomy is performed for some reason other than cervical cancer, there are no risks
for developing precancerous lesions and hence cervical cancer. So from this state a
woman can either stay at the same state, or die from some cause other than cervical cancer.
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14. Cancer Survivor: Cervical cancer survivor five years after cervical cancer diagnosis
and treatment.
Women at this state, can remain in the same state, or die from some cause other than
cervical cancer. This is actually a limitation of the model since there is a risk of cervical
carcinogenesis after successful treatment, but this is how all studies found model cervical
carcinogenesis including the Siebert et al. (2006) model. This however, has negligible
affect on the results of this thesis which are the best ages screenings should occur. This is
because the age specific risks of CIN (which are the primary factor that determines the best
ages screening should occur, as it will be indicated in Chapter 4) are negligibly affected by
this limitation.
15. Cancer Death: Death due to cervical cancer.
Women in this state stay in this state.
In the developed model, while in this state, women still move on with their lives as if they
did not die cancer and may “die” from some cause other than cervical cancer, in order to
record the number of years each woman would have had, had she not died from cervical
cancer. These recorded “life years lost” will be used as a means to optimize the screening
strategies with respect to life years saved in the screened population. This is discussed in
more detailed in Section 3.3 where the formulations of the optimization models are
discussed.
16. All Cause Death: Death due to causes other than cervical cancer.
Women at this state remain at this state.
In the developed model, women are disposed from the simulation at this state.
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Note that benign hysterectomy and all cause death transitions probabilities are
independent transition probabilities from all the other ones. All other transition
probabilities describe the progression of cervical carcinogenesis over time for a cohort of
women. Benign hysterectomy and all cause death transition probabilities, however,
remove women from this progression, since when a woman has a benign hysterectomy or
dies from some other cause, there is no longer an issue of cervical carcinogenesis. The
result of this is that the model is not a pure Markov process. To indicate that transition
probabilities for benign hysterectomy and all cause death are independent from the rest
transition probabilities which describe the progression cervical carcinogenesis, their arrows
in Figure 3 are colored blue, as opposed to black.
The fact that the model is not a pure Markov process does not affect the analysis
that can be achieved with this model because it is modeled as a simulation, but it does have
some implications to the structure and the parameters of the model. In Section 2.3 it was
mentioned that since a Markov process must make a transition into some state over one
Markov cycle, then the transition probabilities pij for each state i to some state j must
s

satisfy the property

∑p

ij

= 1 , i = 1,..., s are the states of the process. Since the transition

j =1

probabilities for benign hysterectomy and all cause death are independent probabilities,
their transition probabilities should not be included in this sum. With respect to the
structure of the process, the implication is that at each state the model needs to first check
if a woman has been removed from the progression of cervical carcinogenesis either
through benign hysterectomy or all cause death. Provided that she has not, then the
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transition probabilities for all other states can be considered. For example, when a woman
is at the CIN I state, the model first needs to check if the woman has died from some cause
other than cervical cancer over that Markov cycle. Provided that she has not, then the
model needs to check if she has had benign hysterectomy over that Markov cycle. If
neither of the two has occurred, then the model can apply the transition probabilities that
describe the progression of cervical carcinogenesis. For states after cancer incidence, since
benign hysterectomy is no longer a possibility, the model must only check if the woman
has died from some cause other than cervical cancer.
Tables 1 through 3 summarize the parameters used in the natural history sub-model
as taken from Siebert et al. (2006): The annual transition probabilities that describe the
natural history of cervical carcinogenesis, the five-year survival rates for cancer after
detection and treatment, and the annual transition probabilities that remove women from
the cervical carcinogenesis process, namely the annual hysterectomy and annual all cause
death rates. The Siebert et al. (2006) model did not include the all cause death rates used,
so US 2003 death rates, taken from the Centers for Disease Control and Prevention
website, were used instead. Due to the fact that all cause death rates are transition
probabilities that remove women from the natural history of cervical carcinogenesis
process rather than describing it, using the US 2003 death rates would have no impact to
the validity of the model.
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Table 1: Cervical Carcinogenesis Natural History Transition Probabilities
Origin State
Destination State
Age
Annual Probability
Well
CIN I
15-85
0.0017 - 0.0521
CIN I
CIN II
15-34
0.0173
35-85
0.0595
CIN II
CIN III
15-85
0.0567
CIN I
Well
15-34
0.1027
35-85
0.0645
CIN II
Well
15-34
0.1027
35-85
0.0645
CIN III
Well
15-85
0.0567
CIN III
Undiag. FIGO I
15-85
0.0410
Undiag. FIGO I
Undiag.FIGO II
15-85
0.2015
Undiag. FIGO II Undiag. FIGO III
15-85
0.2592
Undiag.FIGO III Undiag. FIGO IV
15-85
0.3624
Undiag. FIGO I
Diag. FIGO I
15-85
0.1098
Undiag. FIGO II Diag. FIGO II
15-85
0.2150
Undiag. FIGO III Diag. FIGO III
15-85
0.6120
Undiag. FIGO IV Diag. FIGO IV
15-85
0.9000
Table 2: Five-year Survival Rates for Cervical Cancer after Diagnosis and Treatment
Cancer State
5-year survival rate
FIGO I
0.943
FIGO II
0.736
FIGO III
0.594
FIGO IV
0.238
Table 3: Transition Probabilities that Remove Women from the Cervical Carcinogenesis
Progression
All cause death rates
Benign hysterectomy rates
Ages
00 - 09
10 - 14
15 - 20
20 - 24
25 - 34
35 - 44
45 - 54
55 - 64
65 - 74
75 - 85

Annual Probability
0.001350
0.000159
0.000401
0.000473
0.000640
0.001488
0.003169
0.007380
0.018647
0.018647

Ages
15-35
35-39
40-44
45-49
50-85

Annual Probability
0
0.0113
0.0107
0.0107
0.0060
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3.1.2 Assumptions and Logical Structure of the Screening and Treatment Sub-model
In the simulation, when a woman has a Pap smear scheduled, which is determined
by her age, she is sent from the natural history sub-model to the screening and treatment
sub-model. First a Pap smear test is performed. If the test is negative, the woman is sent
back to the natural history sub-model to the same state that she was when she left it. If the
test result is positive for abnormal cells, women undergo treatment by the methods
described in Section 1.7. Table 4 summarizes the Pap smear sensitivity and specificity
rates. It is assumed that after a positive Pap smear, a cone biopsy is performed to
accurately establish the correct classification of the abnormality. All treatments are
considered to be 95% effective, which is consistent with effectiveness levels used in other
studies (e. g., Maxwell et al. 2002, Mandelblatt et al. 2002). If treatment is successful, the
woman is sent back to the well state in the natural history sub-model. If treatment is
unsuccessful, the woman is returned to the natural history sub-model to the same state that
she was when she left it. If the test is positive for cancer, then the woman is sent to the
appropriate diagnosed FIGO state where she will be treated for cervical cancer according
to the stage of the cancer, as described in Section 1.8.
Compliance levels of women, which describe their willingness to follow up on
screening and treatment, were considered to be 100%. This is not a realistic assumption so
it warrants some explanation. Since compliance levels in the literature are not age
dependent, changes in their levels do not affect the best ages screenings should occur.
Putting lower compliance levels however, would increase the variance of the outputs of the
simulation which in turn would effect how reliably the optimization would reach the
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optimum screening ages. Furthermore, it is desirable to show the potential health benefits
of the recommended screening policies if followed fully. Once the recommended
screening policies are determined, lower compliance levels can be applied for the costeffectiveness analysis that reflect the specific population in question.
It was also assumed that no surveillance after treatment for abnormal smears was
performed (where follow up Pap smears are performed to confirm that treatment was
successful) which is not a realistic assumption in high income settings. The reason for this
is because surveillance strategies vary greatly among different populations of interest from
no surveillance in settings where only a few lifetime screenings are available, to
surveillances that can last up to two years in populations where large numbers of lifetime
screenings are available. Adding surveillance strategies would have negligible affect on
the optimum screening ages (due to the negligible impact on the age specific risks of CIN)
especially when the number of lifetime screenings is large where surveillance strategies
exist. So, in order to maintain a general pertinence for the model no surveillance strategy
was added to the model. Again, once the recommended screening policies are determined,
population specific surveillance strategies can be considered when cost-effectiveness
analysis is performed.

Table 4: Pap smear Sensitivity and Specificity Rates
State
Specificity (%) Sensitivity (%)
Well
95%
CIN I
47.1%
CIN II
71.8%
CIN III
71.8%
Undiag. FIGO I - IV
71.8%
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3.2 Construction, Verification, and Validation of the Model
3.2.1 The Cervical Cancer Discrete Event Simulation Model
A discrete event simulation model was built as described in Section 3.1 using the
Arena software, version 10.00.00 developed by Rockwell Software, Inc. A discrete event
simulation represents a system as a chronological sequence of events that occur in discrete
points over time. Each event marks a change in the system. Figure 4 depicts the cervical
cancer simulation model in Arena.
As can be seen in Figure 5, there are three major parts to the visible part of the
simulation. The first part is the natural history sub-model, which deliberately looks very
similar to the graphical representation of the Markov process depicted in Figure 4. While
the simulation is running, the woman that is currently going through her lifespan in the
simulation can be seen moving through the different health states to provide an image of
her current status with respect to cervical cancer. The second visible part of the model is
the screening and treatment sub-model. When a screening is scheduled at a specific age,
the woman currently in the simulation is routed from the natural history sub-model to the
screening and treatment sub-model. After she goes through screening and treatment, she is
sent back to the appropriate state in the natural history sub-model. The third and final
visible part of the simulation is titled “Current Individual” and is purely for visualization
purposes. It provides an account of the current status of the woman currently in the
simulation (i.e. current age, current health status, age for the next scheduled screening, and
the number of the next screening).
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Figure 4: The Cervical Cancer Simulation Model in Arena
3.2.2 Model Verification
Verification is the process of ensuring that the logical structure of the developed
model is as it was intended (i.e. as described in Section 3.1). The main technique that was
used was following the women step by step as they moved through the simulation to make
sure that the logic they followed was correct. At the same time, the all the parameters in
the simulation were kept track of to ensure that the simulation was reading the correct
parameter values at each point of the simulation. In addition, alternative values to the
parameters were used to create more predictable conditions and confirm that the simulation
was behaving according to the parameter values used.

3.2.3 Model Calibration and Validation
Model validation is the process of ensuring that the developed model behaves the
same way as the real system that is being simulated. In the particular case of this study,
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since the natural history parameters used were from the Siebert et al. (2006) model, crossmodel validation had to be performed to ensure that the predictions of the developed model
in the absence of screening agreed with the predictions of the Siebert et al. (2006) model.
In addition, in the parameters provided in the Siebert et al. (2006) model, the set of
parameters that describe the transition probabilities from Well to CIN I were not explicitly
defined for different ages. It was only known that the transition probabilities ranged from
0.0017 - 0.0521 for ages 15 to 85, as it can be seen in Table 1. Therefore, calibration was
performed on these parameters, which is the process of changing values of model input
parameters within a plausible range, in an attempt to match model output with an observed
set of data.
The developed model was calibrated and validated based on all the Siebert et al.
(2006) model predictions in the absence of screening. As mentioned in the introduction of
Chapter 3, one of the advantages of the Siebert et al. (2006) model was that it provided
many predictions of the model in the absence of screening, which allowed a detailed
calibration to be performed. Figure 5 and Table 3 summarize all the provided predictions.
Figure 6 depicts the age-specific CIN I - III prevalence in the population, which is
particularly useful in calibrating the transition probabilities from Well to CIN I. Table 3
summarizes predictions that regard cervical carcinogenesis on the entire population such as
peak ages for CIN I- III prevalence and cancer incidence, lifetime risk of cervical cancer,
and the distribution of symptoms development for all the FIGO states.
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Figure 5: Age-specific CIN Prevalence from the Siebert et al. (2006) Model

In order to calibrate the Well to CIN I transition probabilities, the age-specific
prevalence of CIN I of Figure 5, were extracted for all ages. Then calibration was
performed through optimization, by determining the Well to CIN I transition probabilities
that minimize the deviation of the age-specific prevalence rates provided by the model and
the ones provided from Figure 5. The values of the transition probabilities for each age
were restricted between 0.0017 - 0.0521 as reported in Siebert et al. (2006). The
optimization model used was
i =85

min ∑ CINI i − CINIOBSi
i =15

Subject to:
0.0017 ≤ WellToCINI i ≤ 0.0521 , i=15, …, 85
where
CINI i is the CIN I prevalence at age i from the Siebert et al (2006) model,
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CINIOBSi is the CIN I prevalence at age i observed in the developed model, and
WellToCINI i is the transition probabilities from Well to CIN I which were determined by
the optimization.
After the Well to CIN I transition probabilities were calibrated, cross model
validation was performed, which is summarized in Table 5 and Figure 6. Figure 6 depicts
the age-specific prevalence rates of CIN I – III and total CIN as predicted by the developed
model, along with the CIN I prevalence as predicted by the Siebert et al. (2006) model. It
can be seen from Figure 6 that the CIN I prevalence rates from the developed model and
the Siebert et al. (2006) model match exactly. Also the CIN II, CIN III, and CIN Total
prevalence rates from the developed model match with the prevalence rates of the Siebert
et al. (2006) model depicted in Figure 5.
Table 5 summarizes all other cross-validation predictions between the developed
model and the Siebert et al (2006) model. For the peak ages of CIN II and CIN II there are
ranges of ages instead of one age because those ages exhibited the same prevalence rates at
three decimal points. Peak age for cervical cancer incidence also has a range of ages
because those ages have the same cancer incidence within plus or minus one cancer per
100,000. The discrepancy in cervical cancer deaths is due to the fact that the developed
model, unlike the Siebert et al. (2006) model, incorporated that during the five years after
cancer detection and treatment, at which the five year survival rates are imposed, women
could also die from other causes. The “percentage of symptoms developed” predict what
percentage of cancers developed symptoms at each cancer state in the absence of
screening. Figure 7 depicts age-specific cancer incidence, cancer symptoms incidence and
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cancer death incidence as predicted from the developed model; the Siebert et al. (2006)
model did not provide figures for these predictions to allow comparison.

Table 5: Model Prediction and Cross-model Validation Values
Model Predictions
Siebert et al.
Developed model
Peak age (years) of CIN I
25
25
Peak age (years) of CIN II
38
32-39
Peak age (years) of CIN III
48
43-47
Peak age (years) of cervical cancer incidence
51
40-47
Peak incidence of cervical cancer (per 100,000)
84
95% C.I. (75.2, 82.4)
Cervical cancer incidence (per 100,000)
3032
95% C. I. (3018, 3054)
Cervical cancer death (per 100,000)
1004
95% C. I. (817, 837)
Percentage of symptoms developed at FIGO I
38.8%
36.3%
Percentage of symptoms developed at FIGO II
31.6%
29.5%
Percentage of symptoms developed at FIGO III
24.1%
22.1%
Percentage of symptoms developed at FIGO IV
5.45%
5.1%
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Figure 6: Age-specific CIN Prevalence from Simulated Model
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Figure 7: Cervical Cancer, Cervical Cancer Symptoms and Cervical Cancer Death
Incidences as Predicted from the Developed Model

3.3 Formulation of the Optimization Model
Once a model has been verified and validated, it can be used to perform various
analyses with. The goal of this study is to show the advantages of constructing the
efficiency curve to be used for cost-effectiveness analysis, through repeated optimization
on the health benefits subject to the number of lifetime screenings available. So the first
step is to formulate the appropriate optimization model. This means determining the
appropriate objective to be maximized or minimized, a set of control variables that can be
changed during the optimization process, and a set of constraints on the control variables
that may be needed to enforce certain requirements.
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The objective function quantifies the measure of performance that alternative
screening strategies are evaluated with, which in this case are the expected (average) health
benefits that result from the screening strategies. Health benefits from cervical cancer
screening can be defined in three ways; the expected reduction in cancer incidences, the
expected reduction of cancer deaths, and the expected life years saved in the screened
population. Which measure of health benefits is the most appropriate is subjective, so
optimizations are performed for all three measures and the tradeoffs between them are
analyzed. Minimizing the expected cancer incidences and the expected cancer deaths is
straightforward with the discrete event simulation model that was constructed because it
records the cancer incidences and cancer deaths as they occur in the simulation.
Evaluating alternative screening strategies with respect to the life years saved
(LYS) in the screened population is an important alternative measure of the health benefits.
This is because unlike cancer incidence and cancer deaths, LYS distinguishes if a cancer
incidence or death was averted from a woman of young age (and therefore saving many
life years) or from a woman of old age (and therefore saving just a few years of life).
Maximizing with respect to the expected LYS is not as straight forward however because
less than 1% of the screened population is expected to die from cervical cancer in the
absence of screening, so less that 1% receives improvement with respect to life years. This
improvement gets diluted in the life years of the remaining population which results to
very small overall improvement in life years due to screenings. These small improvements
along with the stochastic nature of the model would make it infeasible for the optimization
algorithm to work properly by maximizing the expected life years of the screened
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population. This is because the optimization algorithm would not be able to distinguish if
an increase in the expected life years in the population is actual improvement or a result
from noise due to the stochastic nature of the model.
To overcome this difficulty, the LYS in the screened population have to be isolated
somehow, so that they can be measured. To achieve this, in the discrete event simulation
model that was developed, when women move to the cancer death state, instead of being
disposed, they are allowed to move on with their lives as if they did not die from cancer
and may still “die” from some cause other than cervical cancer. In this sense, the cancer
death state behaves like a pseudo-Markov state in the simulation, since women reaching
this state should have been disposed from simulation as they are when they reach the all
cause death state. Letting them stay in the simulation allows the simulation to record the
number of years each woman would have lived more, had she not died from cervical
cancer at the age that she did. Minimizing the expected “life years lost” (LYL) is
equivalent to maximizing the expected LYS from the screened population.
Control (or decision) variables are variables that can be changed during the
optimization process with the goal of improving the performance of the system. In other
words, they represent the available decisions in order to achieve the objective. The
decisions that need to be made are the ages each screening is to be performed. Based on
the number of lifetime screenings available, there needs to be an equivalent number of
variables that represent the ages those screenings are to be performed. Furthermore, since
each decision is some age, the decision variables need to be positive integers. More
formally the control variables are
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X i = the age the ith screening is to be performed, i = 1… n, X i ∈ Ζ + ,
where n is the number of lifetime screening available.
The optimization model could have been equivalently modeled as a binary integer model
by setting binary control variables Yt , t = 15,...,85 where Yt = 1 if screening is performed at
age t, and Yt = 0 otherwise. This formulation however would not have been as practical to
apply on the simulation model.
Constraints are relationships that involve the control variables, and possibly other
parameters of the model, that enforce certain requirements to be satisfied. The first
requirement about the screening ages is that they should be performed during the time
horizon of consideration of the model. So each screening age needs to be between 15 and
85 years of age. More formally, the first set of constraints is
15 ≤ X i ≤ 85 , i = 1,..., n .
The second set of constraints enforced in the optimization model is that the first screening
age needs to be smaller than the second screening age, which needs to be smaller than the
third screening age, and so on. More formally,
X i + 1 ≤ X i +1 , i = 1,..., n − 1 .
This set of constraints is not essential for the optimization model to work properly, but it
does help to greatly reduce the number of solutions being considered. For example,
consider three lifetime screenings without the second set of constraints being imposed.
Then for the optimization algorithm, the solution X1=23, X2=28, X3=32, is different from
solution X1=28, X2=32, X3=23. In fact all 3! (= 6) rearrangements of the three ages, which
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define the same screening strategy, are considered as different solutions from the
optimization model. So when n lifetime screenings are available, the second set of
constraints, reduces the number of solutions to be considered by a factor of n!.
The formulation of the optimization model is then as follows:
Min f ( X ) = E[Cancer incidences(X)] OR E[Cancer deaths(X)] OR E[Life years lost(X)]
Subject to:

15 ≤ X i ≤ 85 , i = 1,..., n
X i + 1 ≤ X i +1 , i = 1,..., n − 1
Xi ∈ Z +

where Xi = the age the ith screening is to be performed,
n = the number of lifetime screenings available, and
X = (X1, …, Xn)

CHAPTER 4 Analysis and Results

This chapter reports and analyzes the results from the simulation optimizations.
First, an overview of the how the simulation optimizations were performed in Arena is
provided. Then, it is shown how the heuristic optimum solutions given by the simulation
optimizations can be used to provide practical screening strategies that can be used as
policy recommendations. Finally, an analysis is performed on those strategies, along with
a comparison to constant interval screening strategies which have been used in practice and
considered in the literature.

4.1 Performing the Simulation Optimizations in Arena
Arena uses a package called OptQuest from OptTek Systems Inc. to perform
simulation optimization. OptQuest intergrades metaheuristics such as Tabu Search, Neural
Networks, and Scatter Search, into a single composite method that is very robust and is
geared towards global optimization. Because metaheuristic algorithms do not explicitly
use derivatives, if they reach a local optimum, they are not aware of it so they can
automatically stop the search. Therefore, a stopping criterion needs to be imposed.
Common stopping criteria used on metaheuristic optimization algorithms are the amount of
56

57
time the algorithm should run, the number of solutions it should examine, or a certain goal
value the objective function should reach.
In order to give the optimization process ample opportunity to reach the global
optimal solution, it was first set to check a minimum of 1,400 solutions. If the best
solution was found on the last 300 solutions checked, it was assumed that further progress
was still likely, and OptQuest was set to run additional simulations until the last 200
solutions that were checked did not provide a better solution. This occurred very few
times in this study and in no cases did the additional solutions checked provide better
solutions, indicating that 1,400 solutions were a sufficiently large to allow the optimization
algorithm to be effective. The expected value at each solution checked during the
optimization was estimated through three replications. Once the search ended, the top 25
solutions were run 30 replications each to get more accurate expected value for each one.
Then, the solution with the best expected value was selected and considered the heuristic
optimum screening strategy. On an Intel ® Pentium ® D CPU 3.40GHz, 2.00 GB of RAM
system, the optimization required approximately 35 hours to run the first 1,400 solutions
and approximately two and a half days to perform the entire optimization process.
For each of the three objective functions that quantify the health benefits resulting
from screening strategies (i.e., cancer incidence, cancer death, and life years lost), twentytwo distinct optimizations were performed, one for each number of lifetime screenings
available from one to twenty two. The decision to stop at twenty-two lifetime screenings
was primarily due to the fact that improvement of the objective functions value from that
point on was very small with respect to all three definitions of health benefits. Also,
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twenty-two screenings is the number of lifetime screenings required by the constant
interval screening strategy of screening every three years from 20 to 85 years of age.
Tables 6, 7, and 8 provide a summary of the heuristic optimum solutions with
respect to cancer incidence, cancer deaths, and life years lost, along with their objective
function values estimated from thirty replications at each solution. Before further analysis
is done on these solutions however, some considerations need to be made. First of all,
since this is a simulation model, the values of different solutions cannot be evaluated
exactly but must be estimated. Furthermore, from the top 25 solutions provided by each of
the optimizations it was indicated that many nearby solutions to the heuristic optimum
solution have objective function values that are not significantly different from (and many
times equal to) those of the heuristic optimums. This is an advantage of the higher level
procedures of metaheuristic algorithms that allow them to escape from local optima and, as
a result, generate multiple alternative solutions while focused on finding the global
optimum. Finally, the optimization model in question is pure integer and is also fairly
nonlinear (as it was found by looking at neighboring solutions of the heuristic optimum
solutions), so calculation of a local gradient to identify whether a solution is a local
optimum does not strictly apply nor it is useful. Keeping all this in mind, a heuristic
optimum solution is not as important in itself, but is rather more important in that it
indicates a small region of the feasible space where solutions exist that have objective
values that are not significantly different from that of the heuristic optimum. From this
point on in the thesis this region will be referred to as the optimality region. This is
advantageous from a practical point of view since for each optimization, a pool of
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available solutions exists rather than just one. The estimated objective values of the
heuristic optimum solutions are important in the sense that they provide a heuristic lower
bound of what is the best that can be achieved with the specific number of lifetime
screenings available from which alternative solutions can be compared to. These facts
about the heuristic optimum solutions can be taken advantage of to construct screening
strategies that not only are as effective as the heuristic optimum solutions but can also be
prescribed as practical screening policies.

Table 6: Heuristic Optimum Solutions With Respect to Cancer Incidence

Table 7: Heuristic Optimum Solutions With Respect to Cancer Deaths
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Table 8: Heuristic Optimum Solutions With Respect to Life Years Lost

4.2 Constructing Practical Screening Strategies from the Heuristic Optimum
Solutions
The heuristic optimum solutions from Tables 6, 7, and 8 are very effective, but they
have one shortcoming compared to the existing, constant interval screening strategies used
in practice. They lack a visible pattern and hence are not as practical to prescribe as
screening policies that can easily be followed, which is an important element for screening
policies in practice. Strategies that have a more visible pattern, while maintaining their
effectiveness, would be more suitable to use as policy recommendations since they are
simpler to understand and hence are more likely to be upheld by the screened population.
So, the fact that each heuristic optimum solution in fact indicates an optimality region was
used to search for smoother, equally effective solutions. Smoothing the solutions had
primarily two goals. The first goal was to provide solutions with constant screening
intervals as much as possible across different age ranges. The second goal was to use
screening ages that had values that were multiples of 2, 5, or 10, since patterns are more
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easily recognizable with such numbers. For example, a smoothed screening strategy with
12 lifetime screenings available could have a screening interval of three years from 22 to
46 years of age and a screening interval of five years from 50 to 60 years of age.
The objective value of a candidate solution was considered not to be significantly
different from that of the heuristic optimum solution if its value estimated from 30
simulation replications fell within the 95% confidence interval of the heuristic optimum
solutions, also estimated from 30 simulation replications. More specifically, since the goal
was to minimize the three objectives (cancer incidence, cancer death, and life years lost), a
candidate smoothed solution had to have an objective value no larger than the value of the
heuristic optimum screening strategy plus the value of its 95% half-width. Thirty
replications where considered sufficiently large since the sizes of the resulting half-widths
were sufficiently small from a practical point of view with respect to all three measures of
performance. The sizes of the half-widths at various levels of cancer incidence, cancer
deaths, and life years lost can be seen in Tables 6, 7, and 8 respectively.
A thorough search for smoother screening strategies was performed for all the
heuristic optimum solutions. From the search for smoother screening strategies it was
observed that for cancer incidence and cancer death, solutions deviating more than two
(sometimes three) years from the ages of the heuristic optimum solutions rarely maintained
objective function values that where not significantly different from the heuristic optimum.
So, the optimality regions for the heuristic optimal solutions for cancer incidence and
cancer deaths had a radius of roughly three years. The deviation that could be made from
the ages of the heuristic optimum solutions with respect to life years lost was larger. The
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reason for this can be seen by considering screening once in a lifetime. By screening at
age 35 versus 33, for example, there is a certain reduction in cancer incidences and cancer
deaths. With respect to life years lost however, that difference is scaled down because the
smaller number of cancer deaths averted by screening at age 33 is balanced out by a larger
number of years saved per cancer death averted, and the fewer number of life years saved
per cancer at age 35 is balanced out by a larger number of cancer deaths averted. As a
result, the optimality region for the heuristic optimal solutions for life years lost was larger,
sometimes extending up to five years.
Within the optimality regions however, not all solutions were not significantly
different from the heuristic optimum. The solutions within the optimality regions also had
to maintain a certain frequency of screening at different age ranges that reflected the risks
of developing abnormal or cancerous cells at those ages. The heuristic optimum solution
with respect to cancer incidence with six lifetime screenings for example was screening at
ages 24, 29, 33, 39, 47, and 52. The smoothed solution of screening at ages 25, 30, 35, 40,
45, and 50 (i.e., screening every five years from ages 25 to 50) maintains a cancer
incidence that is not significantly different from the heuristic optimum not only because
the new ages are at most two ages away from the heuristic optimum ones, but also because
it maintained the frequencies the screenings where performed. The solution of screening at
ages 23, 30, 32, 40, 46, and 53 for example, has screening ages deviate one only year from
the heuristic optimum solution, but it results to significantly higher cancer incidence than
the heuristic optimum, because screening ages 30 and 32 are too close and they leave a big
gap from ages 23 to 30 and ages 32 to 40 compared to the heuristic optimum solution.

63
One result that came from searching for smoother solutions was that, even though
the optimality regions were not very large, there was a great deal of overlap among the
optimality regions of the three objectives. This can be also seen by looking at the heuristic
optimum solutions at Tables 6, 7, and 8. By looking at the heuristic optimum solutions of
cancer incidence and cancer death at Tables 6 and 7 for example, it can be seen that the
solutions are almost identical. In fact the vast majority of the screening ages are two or
less years apart, where the cancer death screening ages are on average one year larger than
the screening ages for cancer incidence. This indicates that optimality regions of cancer
incidence and cancer deaths almost completely overlap. By looking at the heuristic
optimum solutions of life years saved at Table 8, they are slightly smaller than the
screening ages of cancer incidence and cancer death but they where still fairly close to
them, being on average about two to three years smaller that the screening ages for cancer
incidence.
As a result, one set of smoothed screening strategies was constructed with objective
values that were not significantly different from the heuristic optimum objective values
with respect to all three criteria. In addition, in most cases any increase of the objective
values were well within the half-width and in some cases even, solutions were found that
where slightly better than the heuristic optimum found by the simulation optimizations.
The only exceptions were four screening strategies (of 4, 6, 15, and 18 lifetime screenings
available) where life years lost marginally deviated from the 95% confidence intervals of
the heuristic optimum values. All attempts however, to create separate smoothed screening
strategies for those cases resulted to life years lost values so close to the existing strategies
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(within half the half-width of the 95% confidence interval), that one set of smoothed
screening strategies was maintained.
The reason why the optimality regions of the three objectives overlapped was
primarily a consequence of the ability to treat precancerous lesions versus cervical cancer,
and of the natural history of cervical carcinogenesis. It is easier to see first why the
optimality regions of cancer incidence and cancer death overlapped. The effectiveness of a
solution with respect to cancer incidence is primarily determined by the age-specific risks
of CIN, particularly CIN II and CIN III. Overall, good solutions will screen at ages where
the risks of CIN are high. By changing the objective from cancer incidence to cancer death
what is added into consideration besides the age specific risks of CIN, are the age-specific
risks of asymptomatic cancer which are much smaller in comparison to the risks of CIN.
Furthermore, the probability of successful treatment of cancer is smaller than the
probability of successful treatment of precancerous lesions. These factors, as indicated by
the simulation optimizations, were significant enough so that optimality regions of cancer
incidence and cancer death almost completely overlapped.
The reason why the optimality regions of life years lost overlapped with the
optimality regions of cancer incidence and cancer death is because minimizing cancer
incidence and cancer deaths have a bias towards minimizing life years lost. This is
because the risks of CIN (by which the optimized screening strategies with respect to
cancer incidence and cancer death are primarily determined), are higher at relatively
younger ages as can be seen in Figure 6, and cancer deaths averted at younger ages save
more life years. Furthermore, screenings scheduled at older ages are less likely to be
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actually performed, since the older a woman is the more likely she is to be dead or to have
had a benign hysterectomy. As a result, minimizing cancer incidence and cancer deaths
have a bias towards minimizing life years lost as well, and as the optimizations indicated,
this bias along with the larger radius of the optimality regions for life years lost, were
enough so that the optimality regions for life years lost overlapped with the optimality
regions of cancer incidence and cancer death.
Table 9 provides the constructed solutions that are also practical to prescribe as
screening policy strategies, along with constant interval screening strategies of 2, 3, and 5
years considered in the literature and used in practice. Table 10 summarizes their objective
values with respect to all three objective functions. The constructed screening strategies
can prescribe practical screening policies because they are intuitive and easy to follow.
The constructed screening strategies are easy to follow because they all have a visible
pattern which makes them easily understood. More specifically, they can all be partitioned
into age ranges where the screening interval is constant. For example, the constructed
screening strategy with 12 lifetime screenings available can easily be expressed as follows:
“The screening strategy with 12 lifetime screenings available is screening women every
three years from 22 to 46 years of age and screening them every five years from 50 to 60
years of age”. The different age ranges with constant screening intervals are indicated in
Table 9 through different colors for strategies with nine screenings available and up.
Furthermore, the constructed screening strategies are intuitive, since the screening intervals
that they recommend are smaller at ages where the risks of cervical intraepithelial
neoplasia and cervical cancer are higher and larger at ages where the risks are lower.
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Table 9: Screening Strategies Constructed by smoothing the Heuristic Optimum
Solutions, and Constant Interval Screening Strategies

Table 10: Objective Values Output of the Screening Strategies Evaluated from 30
Simulation Replications with Cohorts of 100,000 Women
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4.3 Evaluating the Performance of the Constructed Screening Strategies
The screening strategies obtained by smoothing the heuristic optimum solutions are
very cost-effective; particularly when the number of screenings is small. For example,
screening women only once in their lifetime at the age of 35, reduced cancer incidence by
39% which is also consistent with the results reported by Goldie et al. (2005). Cancer
deaths and life years lost were reduced by approximately 45%. Also, the screening
strategy with just three lifetime screenings reduced cancer incidence, cancer death and life
years lost by at least 70%. Furthermore, the screening strategy with seven lifetime
screenings reduced cancer incidence, cancer death and life years lost by approximately
90%.

4.3.1 Comparison with Constant Interval Screening Strategies
At higher number of lifetime screenings, the effectiveness of the constructed
screening strategies can also be seen by comparing them to constant interval screening
strategies, indicated in Table 9 and their corresponding objective values with respect to all
three objective functions used in the optimizations summarized in Table 10. A constant
interval screening strategy can be compared by two screening strategies: The one that that
provides about the same health benefits as the constant interval screening strategy and the
one that uses the same lifetime screenings as the constant interval screening strategy.
The first constant interval screening strategy that can be used for comparison is
screening every five years from 20 to 84 years of age, which requires 14 lifetime
screenings per woman. By looking at Table 10, it can be seen that the constructed
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screening strategy with nine lifetime screenings performs approximately the same with
respect to cancer incidences (with a cancer incidence of 209 per 100,000 versus 201 per
100,000 resulting with the constant interval screening strategy) and cancer deaths (with 34
cancer deaths per 100,000 versus 30 per 100,000 with the constant interval screening
strategy) and significantly better with respect to life years lost (with 805 life years lost per
100,000 versus 1,082 per 100,000 with the constant interval screening strategy). As a
result the constructed screening strategy with nine lifetime screenings provides about the
same health benefits as the constant interval screening strategy with 40% fewer scheduled
screenings. The constructed screening strategy with 14 lifetime screening performs
substantially better than the constant interval screening strategy: it results to 100 cancer
incidences per 100,000 versus 201 cancer incidences per 100,000 resulting from the
constant interval screening strategy. Also, the constructed screening strategy with 14
lifetime screenings results to 12 cancer deaths per 100,000 whereas the constant interval
screening strategy results to 30 cancer deaths per 100,000. Furthermore, the constructed
screening strategy results to 315 life years lost per 100,000 whereas the constant interval
screening strategy results to 1,082 life years lost per 100,000. As a result, the constructed
screening strategy with also 14 scheduled lifetime screenings results to less than half the
health losses than the constant interval screening strategy with also 14 scheduled lifetime
screenings.
The second constant interval screening strategy that can be used for comparison is
screening every three years from 20 to 85 years of age, which requires 22 scheduled
lifetime screening per woman. By looking at Table 10, it can be seen that the constructed
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screening strategy with 16 lifetime screenings performs the same with respect to cancer
incidence (with a cancer incidence of 72 per 100,000) and cancer deaths (with 9 cancer
deaths per 100,000) and better with respect to life years lost (with 223 life years lost per
100,000 versus 354 per 100,000 with the constant interval screening strategy). So, overall,
the constructed screening strategy with 16 lifetime screenings provides about the same
health benefits as the constant screening strategy of every three years with about 27%
fewer scheduled screenings. The constructed screening strategy with 22 lifetime scheduled
screening performs substantially better than the constant interval screening strategy that
also requires 22 scheduled lifetime screenings: It results to 38 cancer incidences per
100,000 versus 72 cancer incidences per 100,000 resulting from the constant screening
strategy. Also the constructed screening strategy results to 4 cancer deaths per 100,000
whereas the constant interval screening strategy results to 9 cancer deaths per 100,000.
Furthermore, the constructed screening strategy results to 95 life years lost per 100,000
whereas the constant interval screening strategy results to 354 life years lost per 100,000.
So, overall the constructed screening strategy with 22 scheduled lifetime screenings results
to fewer than half the health losses than the constant interval screening strategy with also
22 scheduled lifetime screenings. It is also worth noting that the constructed screening
strategy with 22 lifetime screenings results to the same life years lost (with 95 life years
lost per 100,000) as the constant interval screening strategy of screening every two years
which required 33 scheduled lifetime screenings. As a result, the constant interval
screening strategies are now dominated by the strategies constructed through the heuristic
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optimum solutions since same levels of cancer incidence, cancer deaths, and life years lost
can be achieved with fewer lifetime screenings.

4.3.2 Looking at Other Relevant Output of the Screening Strategies
Although the screening strategies were evaluated with respect to cancer incidences
cancer deaths and life years lost, other relevant output were also kept track by the
simulation model. Table 11 summarizes some of them which are as follows: “Screenings
performed” refers to the actual number of screening performed per 100,000 women for
each screening strategy, as opposed to the scheduled number of screenings performed per
100,000 women which equals 100,000 times the lifetime screening available. “False
positives” refers to the number of false positives resulting per 100,000 women for each
screening strategy. “False positives percentages” refers to the percentage of the actual
screenings performed that resulted in false positive for each screening strategy. “Cancers
Detected by Screening” refers to cancers detected by a Pap smear before the developed
symptoms. “Cancers Detected by Screening (%)” refers to the percentage of the total
cancer incidence that was detected by a Pap smear. “FIGO I – IV Treated” refer to how
many women per 100,000 received treatment for cervical cancer at each FIGO state.
“FIGO Treated Prevented (%)” refers to the percentage of all FIGO treatments prevented
compared to the total number of FIGO treatments in the absence of screening.
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Table 11: Additional Output from the Simulation

The number of women treated for cancer per 100,000 women is an important
measure to keep track of, since treating cancer is not only a painful experience to the
patients, which also results to a reduction to their quality of life after treatment is
completed, it is also far more expensive to treat than precancerous lesions. Costs for
treating precancerous lesions in the United States range from $800 US to $3,200 US
according to the stage of the precancerous lesion, whereas costs for cancer treatment range
from $16,000 US to $45,000 US according to the stage of the cancer (Goldie et al. 2004).
By looking at “FIGO Treated Prevented (%)” in Table 11 it can be seen that FIGO
treatments reduce in similar rates as cancer incidences and cancer deaths prevented (which
can be seen in Table 10), as the number of lifetime screenings increases. As a result,
comparing the constructed screening strategies with the constant interval screening
strategies, provide similar results. Specifically, the constructed screening strategy with
nine (sixteen) lifetime screenings results to the same level of cancer treatments reduction
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as the constant interval screening strategy of screening every five (three) years which
requires fourteen (twenty-two) lifetime screenings.
A measure of performance along the same lines as the number of women treated for
cancer per 100,000, is the percentage of cancers that are detected from screening before
they develop symptoms (if symptoms developed at all). From Table 11 it can be seen that
as the number of screenings increases, the percentage of cancers that are detected by
screening also increases. (The actual number of cancers detected by screening decreases,
because cancer incidence is reduced as the number of lifetime screenings increases). This
indicates the benefits of screening not only in detecting abnormal smears and preventing
cancer, but also in detecting asymptomatic cancer and hence allowing treatment at earlier
stages of the cancer that would otherwise be performed. With treatment at earlier cancer
stages, treatment has higher chances of success, is less costly, and the quality of life of the
patients after treatment is higher because treatment is less intrusive. This health benefit of
screening is also seen in Table 10 where the percentages of cancer deaths prevented, as the
number of screening increases, are higher than the percentages of cancer incidences
prevented. Comparing the screening strategies with the same number of lifetime
screenings to the constant screening interval strategies it can be seen that the constant
interval screening strategies have a much higher percentage of cancers detected. This is
not an advantage towards the constant interval screening strategies however. The reason
why the percentages are higher is because screenings occur with the same frequency at
early ages (where cancer can be prevented) as in later ages (where cancer is more likely to
have been developed) and as a result, the constant interval screening strategies prevent
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fewer cancers at early ages and are more likely to detect them at later ages.
False positives are an important issue when it comes to any type of screening in
medicine, because they cause undue stress and anxiety to the patients, and they also waste
recourses used in further investigation and possibly treatment. This is true for cervical
cancer screening as well. A Pap smear costs about $35 US (Goldie et al. 2004). If the
smear result is positive, it is followed by a colposcopy and biopsy which cost
approximately $450 US (Goldie et al. 2004). Although false positives comprise a small
percentage of the overall number of screenings performed, they result into relatively large
costs. By looking at Table 11, it can be seen that there is a small increase in the percentage
of false positives as the number of lifetime screenings increases. The reason for this
increase is because with larger number of lifetime screenings, a smaller proportion of the
women will have precancerous lesions. As a result, there will be a larger proportion of
women without abnormal lesions, and hence the percentage of false positives will increase.
Although the percentage of false positives increase is small as the number of
lifetime screenings increases, the actual number of false positives increases significantly,
as it can be seen in Table 12. The cohort of screened women in the simulation remains the
same. Hence, it is of interest to also look at the lifetime risks for false positives as the
number of lifetime screenings increases. Thus, for each woman in the simulation, the
number of false positives during her lifetime was recorded in order to provide a probability
distribution of the number of false positives for women under each screening strategy. The
probability mass functions of the probability distributions are summarized in Table 12,
where each row represents a probability mass function. Whereas false positives per
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100,000 women provide a sense of the overall costs resulting from false positives under
each screening strategy, the probability distribution of lifetime risks for false positives
provides a sense of the impact of false positives towards women under each screening
strategy. For example, the optimized screening strategy with nine lifetime screenings per
woman, results to approximately 37,300 false positives per 100,000 women, and women
under this strategy, have about a 68% chance to have no false positives, about 26% chance
to have one false positive, about 5% chance to have two false positives, and about 0.5%
chance to have three false positives in their lifetimes.
The information in Tables 11 and 12 provide a more detailed evaluation of the
constructed screening strategies that also allows a more complete comparison with the
constant interval screening strategies. Recall that the constructed screening strategy with
nine lifetime screenings provides about the same health benefits compared the constant
interval screening strategy with screening every five years which requires 14 scheduled
lifetime screenings. Note that by looking at the actual screenings performed rather than the
scheduled screenings, the constructed screening strategy uses only 21.8% fewer screenings
rather than 40%. The reason for this is because the constant interval screening strategy
has more screenings scheduled at older ages when women are less likely to actually receive
the screening, since the older a woman is the more likely she is to be dead or to have had a
benign hysterectomy. Still however, the constructed screening strategy provides the same
health benefits with substantially fewer screenings. Also, the constructed screening
strategy has 24% fewer false positives than the constant interval screening strategy.
Furthermore, women under the constructed screening strategy have a 68.5% chance to
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have no false positives versus a 61.4% with the constant interval screening strategy.
Comparison between the constructed screening strategy with 16 lifetime screenings and the
constant interval screening strategy of screening every three years, which provide about the
same health benefits result to similar conclusions.

Table 12: Probability Mass Functions of Lifetime Risks for False Positives

4.3.3 Overall Conclusions about Constructed Screening Strategies
After completing the analysis on the constructed screening strategies, we see how
we can use heuristic optimum solutions obtained by simulation optimization, to get equally
effective, smoothed solutions that can serve as practical screening policies. The
constructed screening strategies are particularly cost-effective for small numbers of
lifetime screenings, and are more cost-effective than constant interval screening strategies.
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In particular, the constructed screening strategies can provide the same health benefits with
substantially fewer screenings, false positives, and cancer treatments, all of which result to
a substantial reduction in costs and discomfort to the screened population.

CHAPTER 5 Considerations and Projections of Properly Timed
Screening Strategies in a Post-vaccination Era

This chapter performs an analysis on the impact of HPV 16/18 vaccination on
cervical carcinogenesis, cervical screening, and the heuristic optimum screening strategies
that result from simulation optimizations, as the duration of sustained vaccine immunity
increases. The analysis was performed by creating 40 screening scenarios with varying
durations of sustained vaccine immunity and different number of lifetime screenings
available, which were used to draw general conclusions.
In recent years there has been significant progress in the understanding of the
natural history of cervical carcinogenesis and the causal role of oncogenic strains of the
HPV virus. This understanding let to the development of two vaccines that prevent the
two major oncogenic strains of HPV (16 and 18) which account for approximately 70% of
all cervical cancers (Kohli et al. 2007). Since the developed vaccines provide only a
partial means of prevention against cervical cancer, it is essential that cervical screening is
continued as a supplement to vaccination to provide the best possible prevention (Adams et
al. 2007). As a result, the proper timing of the screenings to maximize their effect towards
combating cancer will be of interest in the post-vaccination era as well. In fact, since the
potential benefits of screenings will be reduced due to the reduced lifetime risk of cervical
77
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cancer after vaccination, the proper timing of the screening will become even more
important. Furthermore, it is likely that vaccination will ultimately change the natural
history of cervical carcinogenesis, especially if the vaccine is found not to have sustained
lifetime immunity. So it is of interest to see if, how, and by how much the screening ages
that result from optimization change at different durations of sustained vaccine immunity.

5.1 Calibration of Model to Incorporate Vaccination and Assumptions Made about
the Vaccine
The simulation model as is now, even with calibration, cannot provide the most
accurate projections of the natural history of cervical carcinogenesis after vaccination
possible, to reflect the understanding of the heterogeneous role of the various oncogenic
strains of HPV. This is because the model does not include the appropriate HPV states in
the natural history of cervical carcinogenesis. Using the best available projections from the
literature on the impact of the HPV vaccine and by considering the models used in those
studies however, the model can be calibrated enough so that it can still provide general
insights and projections on screening strategies that are properly timed through
optimization in a post-vaccination era.
Two findings in the literature helped with the calibration of the model. The first
finding is that vaccination is expected to reduce cancer incidence and cancer deaths by
approximately 70% (Kohli et al. 2007, Adams et al. 2007). The second finding is that
prevention from the HPV 16 and 18 strains from all oncogenic HPV strains, lowers the
progression transition probabilities of “Well to CIN I” and “CIN I to CIN II”. Progression
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transition probabilities from states CIN II onward and all regression transition probabilities
stay the same (Goldie et al. 2003, Kohli et al. 2007). What could not be ascertained
however, is the relative degree to which “Well to CIN I” and “CIN I to CIN II” are
affected. This is because models that were used to study the vaccine also included
transition probabilities from and to various HPV strain groups that captured the
heterogeneous role of those strains groups towards carcinogenesis. So, to minimize error,
it was assumed that both transition probabilities were scaled down by the same degree. So
a scaling factor 0 ≤ α ≤ 1 was introduced to the model to scale the transition probabilities
of “Well to CIN I” and “CIN I to CIN II” so that cancer incidence and cancer deaths were
reduced by 70% if the vaccine has sustained lifetime immunity. As a result the calibrated
model has biased estimates of the prevalence levels of CIN I and CIN II at different ages,
most likely by underestimating CIN I and overestimating CIN II.
Current evidence from clinical trials suggest that the immunity following vaccination
exceeds five years and appears to be sustained (Adams et al. 2007). It is a key unknown,
however, whether the vaccine will portray waning immunity over time. If the vaccine does
portray waning immunity, it is not known in what fashion the immunity of the vaccine will
drop. So in the model it was assumed that if waning of immunity occurs, it will drop from
full to zero immunity with an exponential rate over a period of five years.

5.2 Design of Analysis
The introduction of the vaccine will ultimately change the natural history of
cervical carcinogenesis, especially if the vaccine portrays waning immunity over time. So
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it is of primary interest to see how the screening ages that result from optimizations will be
affected as the duration of sustained vaccine immunity increases. Also, due to the reduced
risks of cervical cancer after vaccination, the potential benefits of cervical screenings will
be reduced, along with increased negative effects on the performance of screenings, such
as increased false positives rates. Such effects can potentially have negative effects on
cervical screening, such as decreased compliance by the population and an increased
fatigue and boredom within the cytology workforce (Adams et al. 2007). So it is also of
interest to see how the risks of cervical carcinogenesis and the performance of screenings
will be affected as the duration of sustained vaccine immunity increases. With these
objectives in mind, eight different scenarios were created where the vaccine sustains full
immunity up to ages 20, 25, 30, 35, 40, 45, 55, and lifetime, and then immunity falls with
an exponential rate to zero immunity over a period of five years (except for lifetime
immunity). On these eight scenarios, simulation optimization was applied to generate
screening strategies with 1, 2, 3, 5, and 8 lifetime screenings available that minimize
cancer incidence, creating 40 screening scenarios from which general conclusions can be
drawn. The results of all simulation optimizations are summarized in Table 13.
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Table 13: Heuristic Optimum Solutions that Minimize Cancer Incidence with 1, 2, 3,
5, and 8 Lifetime Screening as the Duration of Sustained Vaccine Immunity Increases
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5.3 Results and Conclusions
5.3.1 Observations on the Impact of Vaccination on Cervical Carcinogenesis and
Cervical Screening
The first observation on the impact of vaccination on cervical carcinogenesis is that
there are diminishing returns on the health benefits of vaccination, as the duration of
sustained immunity increases. This can be seen in Figure 8, where there are diminishing
returns on the percentage reduction in cancer incidence, cancer deaths and life years lost.
Vaccine efficacy up to age 12 depicts the case of no vaccination on figures in this chapter,
since the body can better produce antibodies at that age and vaccination is recommended
then for maximum immunity (Adams et al, 2007). For example, the vaccine achieves 50%
of its full potential (i.e., reducing cancer incidence and cancer deaths by 70%) if it has
sustained immunity up to approximately 25 years of age and 75% of its full potential if it
has sustained efficacy up to approximately 30 years age. The remaining 25% of its
potential is actualized from 30 years of age onward. This is because the risks of HPV
infection (and as a result the risks of CIN and Cancer) are age dependent, as they are
directly related to sexual patterns in the population, and are higher at younger ages,
primarily at late teens and early twenties.
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Figure 8: Impact of Vaccine on Cancer Incidence, Cancer Deaths, and Life Years
Lost as the Sustained Vaccine Immunity Age Increases

The reduced lifetime risks of cervical carcinogenesis as the vaccine’s sustained
immunity duration increases, naturally lead to a reduction of the benefits screenings can
have towards combating cervical cancer. Specifically, as indicated by Figure 9, the
percentage reduction that is achieved with a specific number of lifetime screenings
available remains approximately the same. These percentages however, are on a
constantly reducing cancer incidence per 100,000 as can be seen in Table 13. One lifetime
screening for example, prevents about 39% of all cancers when vaccine is not introduced
to the population, when vaccine has sustained immunity up to 25 years of age, and when it
has lifetime sustained immunity. When the vaccine is not introduced, one lifetime
screening averts approximately 1,190 cancers per 100,000, whereas with sustained vaccine
immunity up to 25 years of it averts approximately 800 cancers per 100,000, and with
lifetime sustained immunity it averts approximately 350 cancers per 100,000.
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Figure 9: Percentage of Cancer Incidence Reduction with 1, 2, 3, 5, and 8
Lifetime Screenings, as the Sustained Vaccine Immunity Age Increases

In addition to the diminishing benefits of cervical screening due to reduced risks of
cervical cancer, as the vaccine’s sustained immunity duration increases, there are also
negative effects on the performance of screening through increased false positive rates.
Figure 10 indicates the false positive rates for 1, 2, 3, 5, and 8 lifetime screenings, as the
vaccine’s sustained immunity duration increases. The increase in false positives occurs
because with vaccination, a larger proportion of the population will not have precancerous
lesions (CIN) or cancer. So even though the false positive rates of the screening method
remain the same (in this case, the screening method being Pap smear with a 5% chance to
result in a false positive), the overall chance of a false positive result increases.
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Figure 10: False Positive Percentages with 1, 2, 3, 5, and 8 Lifetime
Screenings, as the Sustained Vaccine Immunity Age Increases

Overall, the larger the vaccine’s sustained immunity duration, the greater (though
diminishing) the benefits are towards combating cervical cancer. This paradoxically has
the potential of having a negative impact on cervical screening, which needs to be
continued as a supplement to vaccination due to the partial protection of the vaccine. The
reduced lifetime risks of cervical carcinogenesis will lead to a reduction of the benefits of
cervical screening and an increase in false positive rates. This, as a result could potentially
give a negative perception of cervical screening to the screened population, which can
eventually affect the performance of screening due to reduced compliance rates. As a
result, the value of properly timed screening strategies will be even greater in the postvaccination era, since as the analysis in Chapter 4 indicated, properly timed screening
strategies provide the same health benefits as constant interval screening strategies with
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substantially fewer screenings and fewer false positives, thereby counteracting the
potential negative impact of vaccination towards cervical screening.

5.3.2 Effects of vaccine efficacy duration to the timing of the screening strategies
The introduction of the vaccine will ultimately change the natural history of
cervical carcinogenesis, so it is of interest to see how the heuristic optimum screening
strategies that result from simulation optimization are expected to change at varying
durations of sustained vaccine immunity. Figures 11 and 12 indicate the pattern in which
the screening ages are expected to change. Figure 11 depicts how the optimal screening
age for one lifetime screening changes as the duration of sustained vaccine immunity
increases. The optimal screening age with one lifetime screening without vaccination is
35. The optimum screening age becomes larger as the vaccine’s immunity is sustained up
to 35 years of age, reaching 46 years of age. As the vaccine’s immunity is sustained for
longer periods the optimal screening age becomes smaller, eventually returning back to 35
years of age if immunity is sustained up to 55 years of age or older.
This pattern is maintained for the heuristic optimum screening strategies for all
numbers of lifetime screenings tested. Initially there is an increase on the ages where
screening takes place until vaccine immunity is sustained up to 30 to 40 years of age. If
vaccine immunity is sustained for longer periods the increase grows smaller eventually
becoming either very small or going away, if immunity is sustained up to 55 years of age
or older. Since it is of interest to see the pattern in which the screening ages will change
(the model cannot definitely predict the heuristic optimum screening strategies in the post-
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vaccination era) and since there is not much variation on the change the individual
screening ages portray for each screening strategy, the most clear way to depict this pattern
is through the average change of the screening ages at different durations of sustained
vaccine immunity. Figure 12 depicts the average increase of the ages in which screening
takes place of the heuristic optimum screening strategies for 1, 2, and 3, lifetime
screenings. Screening strategies with 5 and 8 lifetime screenings exhibit the same pattern
but for clarity purposes are not depicted.
This pattern has to do with how different durations of sustained vaccine immunity
affect the relative risks of abnormal cells (i.e., CIN I, CIN II, and CIN III). As mentioned
in Section 4.2, efficient screening strategies have smaller screening intervals at ages where
the risks of CIN are higher, and larger screening intervals where the risks of CIN are lower,
giving greater weight to more advanced levels of CIN because the more advanced CIN
levels are the more likely they are to progress to cancer and to be detected by a Pap smear.
If vaccination alters the ages where the risks are higher, then the heuristic optimum
screening ages also change. Figures A1 to A9 in Appendix A depict the change of the agespecific risks of abnormal cells at different durations of sustained vaccine immunity and
they indicate the same pattern the heuristic optimum screening strategies also change. By
looking at the CIN levels (particularly CIN II and CIN III) as the duration of sustained
vaccine immunity gets larger up to 35 years of age, one can see that (while the absolute
risks continuously become smaller) the relative risks are higher at older and older ages. As
vaccine immunity is sustained for periods longer than 35 years of age, the relative risks are
higher at younger and younger ages. Eventually, when immunity is sustained up to age 55
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and older, the relative risks are essentially the same as in the case of no vaccination, just
shifted down since the absolute risks are now smaller.
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Figure 11: Optimum Screening Age for One Lifetime Screening as the Sustained
Vaccine Immunity Age Increases

Average Screening Age Increase

12.0

9.0

6.0

3.0

0.0
15

25

35

45

55

65

75

85

Sustained Vaccine Immunity Age (Years)
1 Screening

2 Screenings

3 Screenings

Figure 12: Average Increase in Optimum Screening Ages as the Sustained Vaccine
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89
An alterative way of looking at the change in the heuristic optimum screening
strategies as the duration of sustained vaccine immunity increases is by looking at the
difference in efficacy of the constructed (smoothed) screening strategies from no
vaccination when applied to the different scenarios of sustained vaccine immunity, to the
efficacy of the heuristic optimum screening strategies for each specific scenario. Figure 13
depicts the difference in cancer incidence of the constructed screening strategies from no
vaccination, to the heuristic optimum screening strategies for each duration of sustained
vaccine immunity. Comparing the screening strategies this way, has the advantage that it
can distinguish if the constructed screening strategies from no vaccination have
significantly different cancer incidence from the heuristic optimum screening strategies for
each duration of sustained vaccine immunity (“significantly different” is defined here the
same way as in Section 4.2). This renders the ability to distinguish if the smoothed
screening strategies from the case of no vaccination are expected to change given the
duration of sustained vaccine immunity. By considering the half-widths of the heuristic
optimum solutions from Table 13 and the cancer incidence difference from Figure 13, the
smoothed screening strategies from the case of no vaccination are not expected to change if
vaccine immunity is sustained up to 55 years of age or older. It should be noted however,
that given the limitations of this model, age 55 is the best estimate with the available data,
for the lowest duration of sustained vaccine immunity where the smoothed screening
strategies from the case of no vaccination are not expected to change.
In the cases where the screening strategies are expected to change however, it is
worth noting that (especially when more than 3 lifetime screenings are available) the
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changes of the optimum screening ages will not be dramatic. This can be seen by looking
at the screening strategies for 5 and 8 lifetime screenings for different durations of
sustained vaccine immunity in Table 13. There seems to be a perception however, that in
the post-vaccination era, screening will be more important as a supplement to vaccination
after the vaccine starts portraying waning immunity (Adams et al. 2007). This is a crude
way of projecting the change of screening strategies in the post-vaccination era even at the
qualitative level. As the 40 screening scenarios in this chapters’ analysis emphasized,
when screening is more important is primarily related to the relative risks of CIN at
different ages. As a result, how screening will best supplement vaccination in the postvaccination era will depend on how vaccination will affect those risks. As can be seen in
Figures A2 to A9, even at ages where vaccination sustains its immunity, most of the times
the risks are still higher than in ages where vaccine immunity has worn off, and that is why
the heuristic optimum screening ages did not have dramatic changes for different durations
of sustained vaccine immunity.
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Cancer Incidence Increase (per 100,000)
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Figure 13: Cancer Incidence Difference of Constructed Screening Strategies from no
Vaccination to Heuristic Optimum Screening Strategies for each Scenario of
Sustained Vaccine Immunity

5.4 Overall Conclusions
In the post-vaccination era, the importance of properly timed screening strategies,
which can be attained through optimization, will be greater. This is because the reduced
lifetime risks of precancerous lesions and cancer will lead to a reduction of the health
benefits of cervical screening and an increase in false positive rates. These effects could
potentially give a negative perception of cervical screening to the screened population
which can lead to reduced compliance rates. Properly timed screening strategies however,
can counteract both these effects, since they can provide the same health benefits with
substantially fewer screenings and false positives.

92
Vaccination will ultimately change the natural history of cervical carcinogenesis,
and has the potential of changing the constructed screening strategies that resulted from the
case of no vaccination. Analysis indicates that if the duration of sustained vaccine
immunity does not last beyond approximately 55 years of age, the timing of the screening
strategies is expected to change by screenings at older ages. This change however will not
be dramatic, especially when the number of lifetime screenings is greater than three. This
is because the proper timing of the screenings does not depend on the age the vaccine
portrays waning immunity, but on the way the relative risks of CIN are affected by
different durations of sustained vaccine immunity which will not be dramatic.

CHAPTER 6 Concluding Remarks and Future Work

6.1 Major Contributions of the Thesis
Cervical cancer is a leading cause of cancer related deaths among women. Due to
the asymptomatic nature of the disease until it is in its advanced stages, screening is of
central importance as a means of prevention, and reduction of mortality and suffering from
the disease. Since the risks for cervical intraepithelial neoplasia (CIN) and cervical cancer
vary by age, simulation optimization can be applied on models that simulate the natural
history of cervical carcinogenesis to maximize the impact of screenings in combating
cervical cancer, by determining the optimal ages to perform them.
This study demonstrated how simulation optimization can be applied on a discrete
event simulation model to obtain efficient screening strategies that are also practical to
serve as screening policies. By performing optimizations for each number of lifetime
screenings available from one to twenty two, efficient screening strategies for any given
amount of resources available were provided. Even though three separate sets of
optimizations were performed (one minimizing cancer incidence, one minimizing cancer
death and one minimizing life years lost), it was able to construct one set of screening
strategies with objective values that were not significantly different from the heuristic
optimum objective values with respect to all three criteria.
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The screening strategies that were created for each number of lifetime screenings
available combined, resulted in the construction of an efficiency curve. The efficiency
curve indicated that the constant interval screening strategies were dominated by the
constructed screening strategies which provided equal health benefits with less screenings,
false positives, and cancer treatments. Of particular interest were also the results for
optimal screening strategies with small number of lifetime screenings. Given 100%
compliance rates by the screened population, with just one lifetime screening available,
cancer incidence was reduced by 39%, and cancer deaths and life years lost were reduced
by approximately 45%. With just three lifetime screenings cancer incidence, cancer
deaths, and life years lost were all reduced by at least 70%. Furthermore, the screening
strategies with seven lifetime screening reduced cancer incidence, cancer deaths, and life
years lost by approximately 90%. These results indicate that constructing such strategies
through optimization for low to middle resource settings, can provide great benefits. By
using the constructed efficiency curve, cost effectiveness analysis can be performed so that
the most appropriate policy can be found, relative to the available recourses that can be
applied to screening in the population of interest.

6.2 Future Considerations
Even though the screening strategies provided in this thesis are most likely
appropriate to at least Western European countries and the United States, the primary goal
of this thesis was to serve as a prototype study to show how optimization can be applied to
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provide efficient screening strategies by properly timing the screenings. More work can be
done in this direction when considering more specific populations of interest or more
specific questions about screening strategies. Some examples of possible future work can
actually be indicated by considering some of studies already done and mentioned in the
literature review.
Two such examples are the Goldie et al. (2001) and Goldie et al. (2005) studies that
looked into cervical cancer screening policies for low-recourse settings. By having a
specific population of interest, the study could also consider specific costs, compliance
levels, surveillance types, and alternative screening methods like visual inspection and
HPV testing which seemed to offer effective screening alternatives for low resource
settings. By also using optimization, they would also determine the best ages the
screenings should be performed and result to screening strategies that were even more
cost-effective.
Another example was the Mandelblatt et al. (2002) study that aimed to compare the
cost-effectiveness of various screening strategies, by considering alternative methods of
screening. The three screening methods that were considered where HPV DNA screening
by itself, Pap smear by itself, and HPV DNA screening combined with Pap smear
screening. The study concluded that HPV testing plus Pap tests every two years appear to
save additional life years at reasonable costs. If in addition to the specific costs and
efficacies of the alternative screening strategies, optimization was used to determine the
best ages the alternative screening methods are to be performed, the results would again be
more cost-effective strategies.
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Furthermore, screening strategies in the post-vaccination era will have to be revised
when more information is known about the vaccine’s impact on the natural history of
cervical carcinogenesis, and on the vaccines efficacy over time. As the analysis in Chapter
5 indicated, properly timing the screenings in the post-vaccination era will be of greater
importance due to reduced lifetime risks of precancerous lesions and cancer in the
vaccinated population. In general, no matter what specific questions are being considered
regarding cervical screening, by using optimization to also determine the best ages
screenings are to be performed, the results will always be more cost-effective.
The improvements in cost-effectiveness for cervical cancer screening strategies
indicate the potential benefits of properly timing the screenings for other screened diseases
as well. As this study indicated, the greater the costs of screening, the greater the chance
of false positives, and the smaller the lifetime risks for contracting a disease, the greater the
value is of properly timing the screenings for optimal performance. Perhaps the most
promising potential lies in breast cancer screening. Not only breast cancer is the second
leading cause of cancer death in women after lung cancer (NCI 2008), the timing of the
screenings through mammography is an issue of concern. Specifically, mammography is
recommended and is cost-effective for women aged 50 to 69 years, but the value of
screening mammography for age ranges 40 to 49 and 70 to 79 is an issue that is studied in
the medical literature (Kerlikowske et al. 1999, Salzmann et al. 1997). Such studies
however (and other studies in the literature) also only consider a limited number of
predetermined screening strategies when performing cost-effectiveness analysis. Even
though considering age ranges is an implicit way of capturing timing of the screenings, this

97
most likely will not take advantage of the natural history of breast cancer as much as
optimization set to determine when screening should be performed.
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APPENDIX A

Age-Specific CIN Prevalence for Different Durations of Sustained Vaccine Immunity

Figure A1: Age-specific CIN Prevalence without Vaccination
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Figure A2: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 20
Years of Age

Figure A3: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 25
Years of Age
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Figure A4: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 30
Years of Age

Figure A5: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 35
Years of Age
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Figure A6: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 40
Years of Age

Figure A7: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 45
Years of Age
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Figure A8: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 55
Years of Age
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Figure A9: Age-specific CIN Prevalence for Lifetime Sustained Vaccine Immunity
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